P-047 Effectiveness of TACE as bridge therapy for liver transplant in hepatocellular carcinoma (English)
- New search for: Ribeiro, C.
- New search for: Barreira, J.
- New search for: Parmanande, A.
- New search for: Semedo, P.
- New search for: Semedo, M.
- New search for: Silva, M.
- New search for: Costa, N.
- New search for: Ribeiro, V.
- New search for: Coimbra, E.
- New search for: Barroso, E.
- New search for: Ribeiro, C.
- New search for: Barreira, J.
- New search for: Parmanande, A.
- New search for: Semedo, P.
- New search for: Semedo, M.
- New search for: Silva, M.
- New search for: Costa, N.
- New search for: Ribeiro, V.
- New search for: Coimbra, E.
- New search for: Barroso, E.
In:
ANNALS OF ONCOLOGY
;
27
;
ii14-ii14
;
2016
-
ISSN:
- Article (Journal) / Print
-
Title:P-047 Effectiveness of TACE as bridge therapy for liver transplant in hepatocellular carcinoma
-
Contributors:Ribeiro, C. ( author ) / Barreira, J. ( author ) / Parmanande, A. ( author ) / Semedo, P. ( author ) / Semedo, M. ( author ) / Silva, M. ( author ) / Costa, N. ( author ) / Ribeiro, V. ( author ) / Coimbra, E. ( author ) / Barroso, E. ( author )
-
Published in:ANNALS OF ONCOLOGY ; 27 ; ii14-ii14
-
Publisher:
- New search for: OXFORD UNIVERSITY PRESS
-
Publication date:2016-01-01
-
Size:ii14-ii14
-
ISSN:
-
Type of media:Article (Journal)
-
Type of material:Print
-
Language:English
- New search for: 616.992
- Further information on Dewey Decimal Classification
-
Classification:
DDC: 616.992 -
Source:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Table of contents – Volume 27
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 1
-
thanks to referees 2015| 2016
- 6
-
The influential and inspirational Gianni Bonadonna's life commitment to evidence-based cancer medicineCurigliano, G. / Valagussa, P. / Veronesi, U. / Gianni, L. et al. | 2016
- 8
-
Annals of oncology in 2015: the year in reviewSoria, J. C. et al. | 2016
- 10
-
Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancerKorn, E. L. / Sachs, M. C. / McShane, L. M. et al. | 2016
- 16
-
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up†Colombo, N. / Creutzberg, C. / Amant, F. / Bosse, T. / González-Martín, A. / Ledermann, J. / Marth, C. / Nout, R. / Querleu, D. / Mirza, M. R. et al. | 2016
- 42
-
Prognostic impact and implications of extracapsular lymph node involvement in colorectal cancer: a systematic review with meta-analysisVeronese, N. / Nottegar, A. / Pea, A. / Solmi, M. / Stubbs, B. / Capelli, P. / Sergi, G. / Manzato, E. / Fassan, M. / Wood, L. D. et al. | 2016
- 49
-
Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysisRaggi, D. / Miceli, R. / Sonpavde, G. / Giannatempo, P. / Mariani, L. / Galsky, M. D. / Bellmunt, J. / Necchi, A. et al. | 2016
- 62
-
Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromesKomrokji, R. S. / List, A. F. et al. | 2016
- 68
-
Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysisLeoncini, E. / Carioli, G. / La Vecchia, C. / Boccia, S. / Rindi, G. et al. | 2016
- 81
-
Fruits, vegetables and lung cancer risk: a systematic review and meta-analysisVieira, A. R. / Abar, L. / Vingeliene, S. / Chan, D. S. / Aune, D. / Navarro-Rosenblatt, D. / Stevens, C. / Greenwood, D. / Norat, T. et al. | 2016
- 96
-
Early market access of cancer drugs in the EUMartinalbo, J. / Bowen, D. / Camarero, J. / Chapelin, M. / Démolis, P. / Foggi, P. / Jonsson, B. / Llinares, J. / Moreau, A. / O'Connor, D. et al. | 2016
- 106
-
Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer†O'Shaughnessy, J. / Campone, M. / Brain, E. / Neven, P. / Hayes, D. / Bondarenko, I. / Griffin, T. W. / Martin, J. / De Porre, P. / Kheoh, T. et al. | 2016
- 114
-
Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study†Tewari, K. S. / Java, J. J. / Eskander, R. N. / Monk, B. J. / Burger, R. A. et al. | 2016
- 121
-
Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02)†Aparicio, T. / Lavau-Denes, S. / Phelip, J. M. / Maillard, E. / Jouve, J. L. / Gargot, D. / Gasmi, M. / Locher, C. / Adhoute, X. / Michel, P. et al. | 2016
- 127
-
Comprehensive analyses using next-generation sequencing and immunohistochemistry enable precise treatment in advanced gastric cancerKuboki, Y. / Yamashita, S. / Niwa, T. / Ushijima, T. / Nagatsuma, A. / Kuwata, T. / Yoshino, T. / Doi, T. / Ochiai, A. / Ohtsu, A. et al. | 2016
- 134
-
Prognostic factors for progression-free and overall survival in advanced biliary tract cancerBridgewater, J. / Lopes, A. / Wasan, H. / Malka, D. / Jensen, L. / Okusaka, T. / Knox, J. / Wagner, D. / Cunningham, D. / Shannon, J. et al. | 2016
- 140
-
A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trialHagman, H. / Frödin, J. E. / Berglund, . / Sundberg, J. / Vestermark, L. W. / Albertsson, M. / Fernebro, E. / Johnsson, A. et al. | 2016
- 147
-
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategiesIlie, M. / Long-Mira, E. / Bence, C. / Butori, C. / Lassalle, S. / Bouhlel, L. / Fazzalari, L. / Zahaf, K. / Lalvée, S. / Washetine, K. et al. | 2016
- 154
-
A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers†Li, B. T. / Drilon, A. / Johnson, M. L. / Hsu, M. / Sima, C. S. / McGinn, C. / Sugita, H. / Kris, M. G. / Azzoli, C. G. et al. | 2016
- 159
-
Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registryWagstaff, J. / Jones, R. / Hawkins, R. / Porfiri, E. / Pickering, L. / Bahl, A. / Brown, J. / Buchan, S. et al. | 2016
- 165
-
Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphomaGupta, M. / Stenson, M. / O'Byrne, M. / Maurer, M. J. / Habermann, T. / Cerhan, J. R. / Weiner, G. W. / Witzig, T. E. et al. | 2016
- 172
-
Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial†Weinstein, C. / Jordan, K. / Green, S. A. / Camacho, E. / Khanani, S. / Beckford-Brathwaite, E. / Vallejos, W. / Liang, L. W. / Noga, S. J. / Rapoport, B. L. et al. | 2016
- 178
-
Metabolic phenotyping of human blood plasma: a powerful tool to discriminate between cancer types?Louis, E. / Adriaensens, P. / Guedens, W. / Vanhove, K. / Vandeurzen, K. / Darquennes, K. / Vansteenkiste, J. / Dooms, C. / de Jonge, E. / Thomeer, M. et al. | 2016
- 185
-
Prospective and clinical validation of ALK immunohistochemistry: results from the phase I/II study of alectinib for ALK-positive lung cancer (AF-001JP study)Takeuchi, K. / Togashi, Y. / Kamihara, Y. / Fukuyama, T. / Yoshioka, H. / Inoue, A. / Katsuki, H. / Kiura, K. / Nakagawa, K. / Seto, T. et al. | 2016
- 192
-
The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC membersMaillet, D. / Blay, J. Y. / You, B. / Rachdi, A. / Gan, H. K. / Péron, J. et al. | 2016
- 199
-
A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapyGrellety, T. / Soubeyran, I. / Robert, J. / Bonnefoi, H. / Italiano, A. et al. | 2016
- 200
-
Two cases of EGFR mutation-positive lung adenocarcinoma that transformed into squamous cell carcinoma: successful treatment of one case with rociletinibHaratani, K. / Hayashi, H. / Watanabe, S. / Kaneda, H. / Yoshida, T. / Takeda, M. / Shimizu, T. / Nakagawa, K. et al. | 2016
- 202
-
More on sunitinib 2 weeks on/1 week off schedule: the Rainbow analysisBasso, U. / Maruzzo, M. et al. | 2016
- 202
-
A rational approach for salvage of testicular cancer patientsSelle, F. / Soares, D. G. / Lotz, J. P. et al. | 2016
- 203
-
Reply to the letter to the editor ‘The ESMO Magnitude of Clinical Benefit Scaling Tool: from theory to practice’ by Hartmann and the letter ‘Comment on ESMO Magnitude of Clinical Benefit Scale’ by Muhonen et al.Cherny, N. I. / Sullivan, R. / Dafni, U. / Kerst, J. M. / Sobrero, A. / Zielinski, C. / de Vries, E. G. / Piccart, M. J. et al. | 2016
- 205
-
How much evidence isn't in evidence-based guidelines?Johnson, M. J. / Currow, D. C. et al. | 2016
- 206
-
PD-L1 copy number gain in nonsmall-cell lung cancer defines a new subset of patients for anti PD-L1 therapyGoldmann, T. / Kugler, C. / Reinmuth, N. / Vollmer, E. / Reck, M. et al. | 2016
- 206
-
Enzalutamide and sleep apnea: an emerging central nervous system side-effect?Labrize, F. / Cany, L. / Massard, C. / Loriot, Y. / Sargos, P. / Gross-Goupil, M. / Roubaud, G. et al. | 2016
- 208
-
Vitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case–Control ConsortiumWaterhouse, M. / Risch, H. A. / Bosetti, C. / Anderson, K. E. / Petersen, G. M. / Bamlet, W. R. / Cotterchio, M. / Cleary, S. P. / Ibiebele, T. I. / La Vecchia, C. et al. | 2016
- 209
-
Planning and reporting of quality-of-life outcomes in cancer trialsSchandelmaier, S. / Conen, K. / von Elm, E. / You, J. J. / Blümle, A. / Tomonaga, Y. / Saccilotto, R. / Amstutz, A. / Bengough, T. / Meerpohl, J. J. et al. | 2016
- 211
-
Environmental emissions, public health and lung cancer riskSwanton, C. / Boffetta, P. / Peston, R. / Soria, J. C. et al. | 2016
- 212
-
Guidelines for endometrial cancer management: finding order amid the uncertaintiesEifel, P. J. et al. | 2016
- 214
-
Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodiesPostel-Vinay, S. / Aspeslagh, S. / Lanoy, E. / Robert, C. / Soria, J. C. / Marabelle, A. et al. | 2016
- 225
-
Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancerDonnem, T. / Kilvaer, T. K. / Andersen, S. / Richardsen, E. / Paulsen, E. E. / Hald, S. M. / Al-Saad, S. / Brustugun, O. T. / Helland, A. / Lund-Iversen, M. et al. | 2016
- 233
-
Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeuticsDimopoulos, M. A. / Kastritis, E. / Ghobrial, I. M. et al. | 2016
- 240
-
Beyond the exome: the role of non-coding somatic mutations in cancerPiraino, S. W. / Furney, S. J. et al. | 2016
- 249
-
Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancerPruneri, G. / Vingiani, A. / Bagnardi, V. / Rotmensz, N. / De Rose, A. / Palazzo, A. / Colleoni, A. M. / Goldhirsch, A. / Viale, G. et al. | 2016
- 256
-
In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer ConsortiumLobbezoo, D. J. / van Kampen, R. J. / Voogd, A. C. / Dercksen, M. W. / van den Berkmortel, F. / Smilde, T. J. / van de Wouw, A. J. / Peters, F. P. / van Riel, J. M. / Peters, N. A. et al. | 2016
- 257
-
Can ovarian suppression with gonadotropin-releasing hormone analogs (GnRHa) preserve fertility in cancer patients?Rodriguez-Wallberg, K. / Turan, V. / Munster, P. / Oktay, K. et al. | 2016
- 262
-
Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer†Mitsuhashi, A. / Sato, Y. / Kiyokawa, T. / Koshizaka, M. / Hanaoka, H. / Shozu, M. et al. | 2016
- 267
-
Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIVLévi, F. A. / Boige, V. / Hebbar, M. / Smith, D. / Lepère, C. / Focan, C. / Karaboué, A. / Guimbaud, R. / Carvalho, C. / Tumolo, S. et al. | 2016
- 274
-
A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinomaRosati, G. / Ambrosini, G. / Barni, S. / Andreoni, B. / Corradini, G. / Luchena, G. / Daniele, B. / Gaion, F. / Oliverio, G. / Duro, M. et al. | 2016
- 281
-
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohortMazières, J. / Barlesi, F. / Filleron, T. / Besse, B. / Monnet, I. / Beau-Faller, M. / Peters, S. / Dansin, E. / Früh, M. / Pless, M. et al. | 2016
- 286
-
Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAILGraff, J. N. / Baciarello, G. / Armstrong, A. J. / Higano, C. S. / Iversen, P. / Flaig, T. W. / Forer, D. / Parli, T. / Phung, D. / Tombal, B. et al. | 2016
- 294
-
Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer†Joseph, N. / Dovedi, S. J. / Thompson, C. / Lyons, J. / Kennedy, J. / Elliott, T. / West, C. M. / Choudhury, A. et al. | 2016
- 300
-
Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumorsCierna, Z. / Mego, M. / Miskovska, V. / Machalekova, K. / Chovanec, M. / Svetlovska, D. / Hainova, K. / Rejlekova, K. / Macak, D. / Spanik, S. et al. | 2016
- 306
-
Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomesLaurent, C. / Delas, A. / Gaulard, P. / Haioun, C. / Moreau, A. / Xerri, L. / Traverse-Glehen, A. / Rousset, T. / Quintin-Roue, I. / Petrella, T. et al. | 2016
- 314
-
Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center studyLassalle, A. / Thomaré, P. / Fronteau, C. / Mahé, B. / Jubé, C. / Blin, N. / Voldoire, M. / Dubruille, V. / Tessoulin, B. / Touzeau, C. et al. | 2016
- 318
-
Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumorsWong, S. J. / Karrison, T. / Hayes, D. N. / Kies, M. S. / Cullen, K. J. / Tanvetyanon, T. / Argiris, A. / Takebe, N. / Lim, D. / Saba, N. F. et al. | 2016
- 324
-
The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06)Strasser, F. / Blum, D. / von Moos, R. / Cathomas, R. / Ribi, K. / Aebi, S. / Betticher, D. / Hayoz, S. / Klingbiel, D. / Brauchli, P. et al. | 2016
- 332
-
Next-generation sequencing of the basal cell carcinoma miRNome and a description of novel microRNA candidates under neoadjuvant vismodegib therapy: an integrative molecular and surgical case studySand, M. / Bechara, F. G. / Gambichler, T. / Sand, D. / Friedländer, M. R. / Bromba, M. / Schnabel, R. / Hessam, S. et al. | 2016
- 339
-
Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance)†Yoon, H. H. / Foster, N. R. / Meyers, J. P. / Steen, P. D. / Visscher, D. W. / Pillai, R. / Prow, D. M. / Reynolds, C. M. / Marchello, B. T. / Mowat, R. B. et al. | 2016
- 344
-
Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole exome sequencing?Postel-Vinay, S. / Boursin, Y. / Massard, C. / Hollebecque, A. / Ileana, E. / Chiron, M. / Jung, J. / Lee, J. S. / Balogh, Z. / Adam, J. et al. | 2016
- 353
-
Access to innovative oncology medicines in EuropeBergmann, L. / Enzmann, H. / Thirstrup, S. / Schweim, J. K. / Widera, I. / Zwierzina, H. et al. | 2016
- 358
-
Prevalence of rare EGFR gene mutations in nonsmall-cell lung cancer: a multicenter study on 3856 Polish Caucasian patientsKrawczyk, P. / Reszka, K. / Ramlau, R. / Powrózek, T. / Pankowski, J. / Wojas-Krawczyk, K. / Kalinka-Warzocha, E. / Szczęsna, A. / Nicoś, M. / Jarosz, B. et al. | 2016
- 359
-
Reply to the letter to the editor ‘Prevalence of rare EGFR mutations in non-small cell lung cancer: a multicenter study on 3856 Polish Caucasian patients’ by Krawczyk et al.Beau-Faller, M. / Cadranel, J. et al. | 2016
- 360
-
KRT81 miR-SNP rs3660 is associated with risk and survival of NSCLCRobles, A. I. / Ryan, B. M. et al. | 2016
- 361
-
Reply to the letter to the editor ‘KRT81 miR-SNP rs3660 is associated with risk and survival of NSCLC’ by Robles et al.Lee, S. Y. / Choi, J. E. / Park, J. Y. et al. | 2016
- 363
-
More colors to the paletteBracarda, S. et al. | 2016
- 363
-
Reply to ‘Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance’ by Funck-Brentano et al.Goldwirt, L. / Chami, I. / Feugeas, J. P. / Pages, C. / Brunet-Possenti, F. / Allayous, C. / Baroudjian, B. / Madelaine, I. / Sauvageon, H. / Mourah, S. et al. | 2016
- 364
-
Reply to the letter to the editor ‘Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumor response and tolerance’ by Funck-Brentano et al.Funck-Brentano, E. / Alvarez, J. C. / Longvert, C. / Abe, E. / Beauchet, A. / Saiag, P. / Funck-Brentano, C. et al. | 2016
- 366
-
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysisBracarda, S. / Iacovelli, R. / Boni, L. / Rizzo, M. / Derosa, L. / Rossi, M. / Galli, L. / Procopio, G. / Sisani, M. / Longo, F. et al. | 2016
- 367
-
Being molecular in the molecular ageRaghupathy, R. / Mok, T. et al. | 2016
- 369
-
Personalized testing based on polygenic risk score is promising for more efficient population-based screening programs for common oncological diseasesRadice, P. / Pharoah, P. D. / Peterlongo, P. et al. | 2016
- 371
-
Stereotactic radiation and checkpoint inhibitors in melanoma patients with BM: a question of drug, timing or both?Dhermain, F. / Deutsch, E. et al. | 2016
- 373
-
Statistical controversies in clinical research: end points other than overall survival are vital for regulatory approval of anticancer agentsSaad, E. D. / Buyse, M. et al. | 2016
- 379
-
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European PanelHadji, P. / Coleman, R. E. / Wilson, C. / Powles, T. J. / Clézardin, P. / Aapro, M. / Costa, L. / Body, J. J. / Markopoulos, C. / Santini, D. et al. | 2016
- 390
-
Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysisFleury, I. / Chevret, S. / Pfreundschuh, M. / Salles, G. / Coiffier, B. / van Oers, M. H. / Gisselbrecht, C. / Zucca, E. / Herold, M. / Ghielmini, M. et al. | 2016
- 397
-
Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working GroupSpano, J. P. / Poizot-Martin, I. / Costagliola, D. / Boué, F. / Rosmorduc, O. / Lavolé, A. / Choquet, S. / Heudel, P. E. / Leblond, V. / Gabarre, J. et al. | 2016
- 409
-
Regulation of PD-L1: a novel role of pro-survival signalling in cancerChen, J. / Jiang, C. C. / Jin, L. / Zhang, X. D. et al. | 2016
- 417
-
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trialSchuler, M. / Yang, J. C. / Park, K. / Kim, J. H. / Bennouna, J. / Chen, Y. M. / Chouaid, C. / De Marinis, F. / Feng, J. F. / Grossi, F. et al. | 2016
- 423
-
Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trialsRamalingam, S. S. / O'Byrne, K. / Boyer, M. / Mok, T. / Jänne, P. A. / Zhang, H. / Liang, J. / Taylor, I. / Sbar, E. I. / Paz-Ares, L. et al. | 2016
- 429
-
Implications of polygenic risk for personalised colorectal cancer screeningFrampton, M. J. / Law, P. / Litchfield, K. / Morris, E. J. / Kerr, D. / Turnbull, C. / Tomlinson, I. P. / Houlston, R. S. et al. | 2016
- 434
-
Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapyAhmed, K. A. / Stallworth, D. G. / Kim, Y. / Johnstone, P. A. / Harrison, L. B. / Caudell, J. J. / Yu, H. H. / Etame, A. B. / Weber, J. S. / Gibney, G. T. et al. | 2016
- 441
-
Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)†Motzer, R. J. / Alyasova, A. / Ye, D. / Karpenko, A. / Li, H. / Alekseev, B. / Xie, L. / Kurteva, G. / Kowalyszyn, R. / Karyakin, O. et al. | 2016
- 449
-
Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)†De Santis, M. / Wiechno, P. J. / Bellmunt, J. / Lucas, C. / Su, W. C. / Albiges, L. / Lin, C. C. / Senkus-Konefka, E. / Flechon, A. / Mourey, L. et al. | 2016
- 454
-
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxelChi, K. N. / Kheoh, T. / Ryan, C. J. / Molina, A. / Bellmunt, J. / Vogelzang, N. J. / Rathkopf, D. E. / Fizazi, K. / Kantoff, P. W. / Li, J. et al. | 2016
- 460
-
Association between PSA kinetics and cancer-specific mortality in patients with localised prostate cancer: analysis of the placebo arm of the SPCG-6 studyThomsen, F. B. / Brasso, K. / Berg, K. D. / Gerds, T. A. / Johansson, J. E. / Angelsen, A. / Tammela, T. L. / Iversen, P. et al. | 2016
- 467
-
Genetic testing in a cohort of young patients with HER2-amplified breast cancerEccles, D. M. / Li, N. / Handwerker, R. / Maishman, T. / Copson, E. R. / Durcan, L. T. / Gerty, S. M. / Jones, L. / Evans, D. G. / Haywood, L. et al. | 2016
- 474
-
Concurrent or sequential letrozole with adjuvant breast radiotherapy: final results of the CO-HO-RT phase II randomized trial†Bourgier, C. / Kerns, S. / Gourgou, S. / Lemanski, C. / Gutowski, M. / Fenoglietto, P. / Romieu, G. / Crompton, N. / Lacombe, J. / Pèlegrin, A. et al. | 2016
- 480
-
Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registryNiikura, N. / Tomotaki, A. / Miyata, H. / Iwamoto, T. / Kawai, M. / Anan, K. / Hayashi, N. / Aogi, K. / Ishida, T. / Masuoka, H. et al. | 2016
- 487
-
Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trialLorusso, D. / Scambia, G. / Pignata, S. / Sorio, R. / Amadio, G. / Lepori, S. / Mosconi, A. / Pisano, C. / Mangili, G. / Maltese, G. et al. | 2016
- 494
-
Prognostic value of tumor-infiltrating lymphocytes in Epstein–Barr virus-associated gastric cancerKang, B. W. / Seo, A. N. / Yoon, S. / Bae, H. I. / Jeon, S. W. / Kwon, O. K. / Chung, H. Y. / Yu, W. / Kang, H. / Kim, J. G. et al. | 2016
- 502
-
A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer†Ueno, M. / Okusaka, T. / Omuro, Y. / Isayama, H. / Fukutomi, A. / Ikeda, M. / Mizuno, N. / Fukuzawa, K. / Furukawa, M. / Iguchi, H. et al. | 2016
- 508
-
Epstein–Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsinKim, S. J. / Kim, J. H. / Ki, C. S. / Ko, Y. H. / Kim, J. S. / Kim, W. S. et al. | 2016
- 513
-
Is it possible to encourage hope in non-advanced cancer patients? We must tryRipamonti, C. I. / Miccinesi, G. / Pessi, M. A. / Di Pede, P. / Ferrari, M. et al. | 2016
- 519
-
Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacyRugo, H. S. / Hortobagyi, G. N. / Yao, J. / Pavel, M. / Ravaud, A. / Franz, D. / Ringeisen, F. / Gallo, J. / Rouyrre, N. / Anak, O. et al. | 2016
- 526
-
A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumorsTolcher, A. W. / Papadopoulos, K. P. / Patnaik, A. / Wilson, K. / Thayer, S. / Zanghi, J. / Gemo, A. T. / Kavanaugh, W. M. / Keer, H. N. / LoRusso, P. M. et al. | 2016
- 532
-
Methanol-based fixation is superior to buffered formalin for next-generation sequencing of DNA from clinical cancer samplesPiskorz, A. M. / Ennis, D. / Macintyre, G. / Goranova, T. E. / Eldridge, M. / Segui-Gracia, N. / Valganon, M. / Hoyle, A. / Orange, C. / Moore, L. et al. | 2016
- 539
-
TP53 mutational status is predictive of pazopanib response in advanced sarcomasKoehler, K. / Liebner, D. / Chen, J. L. et al. | 2016
- 544
-
Successful treatment with an anti-PD-1 antibody for progressing brain metastases in renal cell cancerRothermundt, C. / Hader, C. / Gillessen, S. et al. | 2016
- 545
-
Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapyTannock, I. F. / Sternberg, C. N. et al. | 2016
- 546
-
Idiopathic thrombocytopenic purpura induced by nivolumab in a metastatic melanoma patient with elevated PD-1 expression on B cellsKanameishi, S. / Otsuka, A. / Nonomura, Y. / Fujisawa, A. / Endo, Y. / Kabashima, K. et al. | 2016
- 548
-
Reply to the letter to the editor ‘Can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients?’ by Rodriguez-Wallberg et al.Lambertini, M. / Peccatori, F. A. / Moore, H. C. / Del Mastro, L. et al. | 2016
- 549
-
Reply to the letter to the editor ‘Integration between oncology and palliative care: does one size fit all?’ by Verna et al.Hui, D. / Bansal, S. / Strasser, F. / Morita, T. / Caraceni, A. / Davis, M. / Cherny, N. / Kaasa, S. / Currow, D. / Abernethy, A. et al. | 2016
- 549
-
Integration between oncology and palliative care: does one size fit all?Verna, L. / Giusti, R. / Marchetti, P. / Ficorella, C. / Porzio, G. et al. | 2016
- 550
-
Reply to the letter to the editor ‘How much evidence isn't in evidence-based guidelines?’ by Johnson et al.Cherny, N. I. / Kloke, M. / Cervantes, A. / Pentheroudakis, G. et al. | 2016
- 551
-
Trabectedin is an effective second-line treatment in soft tissue sarcoma patientsPeugniez, C. / Cousin, S. / Penel, N. et al. | 2016
- 553
-
Medication to reduce breast cancer risk: why is uptake low?Butow, P. / Phillips, K. A. et al. | 2016
- 555
-
HER2 imaging in the ZEPHIR studyClark, A. S. / DeMichele, A. / Mankoff, D. et al. | 2016
- 557
-
Another surprising role for exosomes? Improving next-generation sequencing-based cancer diagnostics in liquid biopsiesSzallasi, Z. et al. | 2016
- 559
-
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paperChampiat, S. / Lambotte, O. / Barreau, E. / Belkhir, R. / Berdelou, A. / Carbonnel, F. / Cauquil, C. / Chanson, P. / Collins, M. / Durrbach, A. et al. | 2016
- 575
-
Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysisSmith, S. G. / Sestak, I. / Forster, A. / Partridge, A. / Side, L. / Wolf, M. S. / Horne, R. / Wardle, J. / Cuzick, J. et al. | 2016
- 590
-
Pathways to improving combined modality therapy for stage III nonsmall-cell lung cancerSchild, S. E. / Vokes, E. E. et al. | 2016
- 599
-
IDH mutations in cancer and progress toward development of targeted therapeuticsDang, L. / Yen, K. / Attar, E. C. et al. | 2016
- 608
-
Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysisTruong, J. / Lee, E. K. / Trudeau, M. E. / Chan, K. K. et al. | 2016
- 619
-
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trialGebhart, G. / Lamberts, L. E. / Wimana, Z. / Garcia, C. / Emonts, P. / Ameye, L. / Stroobants, S. / Huizing, M. / Aftimos, P. / Tol, J. et al. | 2016
- 625
-
Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsiesPetrillo, M. / Zannoni, G. F. / Beltrame, L. / Martinelli, E. / DiFeo, A. / Paracchini, L. / Craparotta, I. / Mannarino, L. / Vizzielli, G. / Scambia, G. et al. | 2016
- 635
-
Minimally invasive genomic and transcriptomic profiling of visceral cancers by next-generation sequencing of circulating exosomesSan Lucas, F. A. / Allenson, K. / Bernard, V. / Castillo, J. / Kim, D. U. / Ellis, K. / Ehli, E. A. / Davies, G. E. / Petersen, J. L. / Li, D. et al. | 2016
- 642
-
Clinical correlation of extensive-stage small-cell lung cancer genomicsDowlati, A. / Lipka, M. B. / McColl, K. / Dabir, S. / Behtaj, M. / Kresak, A. / Miron, A. / Yang, M. / Sharma, N. / Fu, P. et al. | 2016
- 648
-
Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas†Ramanathan, R. K. / Goldstein, D. / Korn, R. L. / Arena, F. / Moore, M. / Siena, S. / Teixeira, L. / Tabernero, J. / Van Laethem, J. L. / Liu, H. et al. | 2016
- 654
-
CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancerChiorean, E. G. / Von Hoff, D. D. / Reni, M. / Arena, F. P. / Infante, J. R. / Bathini, V. G. / Wood, T. E. / Mainwaring, P. N. / Muldoon, R. T. / Clingan, P. R. et al. | 2016
- 660
-
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junctionKlevebro, F. / Alexandersson von Döbeln, G. / Wang, N. / Johnsen, G. / Jacobsen, A. B. / Friesland, S. / Hatlevoll, I. / Glenjen, N. I. / Lind, P. / Tsai, J. A. et al. | 2016
- 668
-
Preoperative versus postoperative docetaxel–cisplatin–fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial†Fazio, N. / Biffi, R. / Maibach, R. / Hayoz, S. / Thierstein, S. / Brauchli, P. / Bernhard, J. / Stupp, R. / Andreoni, B. / Renne, G. et al. | 2016
- 673
-
Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma†Al-Batran, S. E. / Van Cutsem, E. / Oh, S. C. / Bodoky, G. / Shimada, Y. / Hironaka, S. / Sugimoto, N. / Lipatov, O. N. / Kim, T. Y. / Cunningham, D. et al. | 2016
- 680
-
A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinomaCiuleanu, T. / Bazin, I. / Lungulescu, D. / Miron, L. / Bondarenko, I. / Deptala, A. / Rodriguez-Torres, M. / Giantonio, B. / Fox, N. L. / Wissel, P. et al. | 2016
- 687
-
Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trialGrenader, T. / Waddell, T. / Peckitt, C. / Oates, J. / Starling, N. / Cunningham, D. / Bridgewater, J. et al. | 2016
- 693
-
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer†Carter, C. A. / Rajan, A. / Keen, C. / Szabo, E. / Khozin, S. / Thomas, A. / Brzezniak, C. / Guha, U. / Doyle, L. A. / Steinberg, S. M. et al. | 2016
- 699
-
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trialsFizazi, K. / Flaig, T. W. / Stöckle, M. / Scher, H. I. / de Bono, J. S. / Rathkopf, D. E. / Ryan, C. J. / Kheoh, T. / Li, J. / Todd, M. B. et al. | 2016
- 706
-
Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO studyPérez-Valderrama, B. / Arranz Arija, J. A. / Rodríguez Sánchez, A. / Pinto Marín, A. / Borrega García, P. / Castellano Gaunas, D. E. / Rubio Romero, G. / Maximiano Alonso, C. / Villa Guzmán, J. C. / Puertas Álvarez, J. L. et al. | 2016
- 712
-
A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomasKim, S. J. / Shin, D. Y. / Kim, J. S. / Yoon, D. H. / Lee, W. S. / Lee, H. / Do, Y. R. / Kang, H. J. / Eom, H. S. / Ko, Y. H. et al. | 2016
- 719
-
Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL)†Cottereau, A. S. / Becker, S. / Broussais, F. / Casasnovas, O. / Kanoun, S. / Roques, M. / Charrier, N. / Bertrand, S. / Delarue, R. / Bonnet, C. et al. | 2016
- 725
-
European cancer mortality predictions for the year 2016 with focus on leukaemiasMalvezzi, M. / Carioli, G. / Bertuccio, P. / Rosso, T. / Boffetta, P. / Levi, F. / La Vecchia, C. / Negri, E. et al. | 2016
- 732
-
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumabFerrucci, P. F. / Ascierto, P. A. / Pigozzo, J. / Del Vecchio, M. / Maio, M. / Antonini Cappellini, G. C. / Guidoboni, M. / Queirolo, P. / Savoia, P. / Mandalà, M. et al. | 2016
- 738
-
Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterationsBousquet, M. / Noirot, C. / Accadbled, F. / Sales de Gauzy, J. / Castex, M. P. / Brousset, P. / Gomez-Brouchet, A. et al. | 2016
- 745
-
The GILDA trial finds no survival benefit from intensified screening after primary resection of colorectal cancer: the PulMiCC trial tests the survival benefit of pulmonary metastasectomy for detected asymptomatic lung metastasesTreasure, T. / Macbeth, F. et al. | 2016
- 746
-
Serum neuron-specific enolase level is an independent predictor of overall survival in patients with gastroenteropancreatic neuroendocrine tumorsvan Adrichem, R. C. / Kamp, K. / Vandamme, T. / Peeters, M. / Feelders, R. A. / de Herder, W. W. et al. | 2016
- 747
-
Number needed to treat for pricing costly anticancer drugs: the example of regorafenib in metastatic colorectal cancerGraziano, F. / Rulli, E. / Biagioli, E. / Catalano, V. et al. | 2016
- 748
-
Genome sequencing for nonsmall-cell lung cancer identifies a basis for nintedanib sensitivity†Takeda, M. / Sakai, K. / Okamoto, K. / Hayashi, H. / Tanaka, K. / Shimizu, T. / Nishio, K. / Nakagawa, K. et al. | 2016
- 750
-
Reply to the letter to the editor ‘Many men with castrate-sensitive metastatic prostate cancer should not receive chemotherapy’ by Tannock et al.Parker, C. / Gillessen, S. / Heidenreich, A. / Horwich, A. et al. | 2016
- 751
-
Survival in young adults diagnosed with follicular lymphomaCalvo, V. / Provencio, M. / Gómez Codina, J. / Rodríguez Abreu, D. / Rueda, A. et al. | 2016
- 752
-
Drug–drug interactions associated with kinase inhibitors: highlighting a new resource for oncologists and clinical pharmacistsGelderblom, H. / Köhne, C. H. / Launay-Vacher, V. / van Leeuwen, R. W. et al. | 2016
- 753
-
Survival after resection of perihilar cholangiocarcinoma—development and external validation of a prognostic nomogramGroot Koerkamp, B. / Wiggers, J. K. / Gonen, M. / Doussot, A. / Allen, P. J. / Besselink, M. G. / Blumgart, L. H. / Busch, O. R. / D'Angelica, M. I. / DeMatteo, R. P. et al. | 2016
- 755
-
PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutationsHelleday, T. et al. | 2016
- 758
-
Reporting incidental germline variants in the context of day-to-day somatic genomic profilingMak, G. / Moschetta, M. / Arkenau, H. T. et al. | 2016
- 760
-
Statistical controversies in clinical research: statistical significance—too much of a good thing …Buyse, M. / Hurvitz, S. A. / Andre, F. / Jiang, Z. / Burris, H. A. / Toi, M. / Eiermann, W. / Lindsay, M. A. / Slamon, D. et al. | 2016
- 763
-
Molecular classification of gastric cancerChia, N. Y. / Tan, P. et al. | 2016
- 770
-
New drugs in acute myeloid leukemiaKadia, T. M. / Ravandi, F. / Cortes, J. / Kantarjian, H. et al. | 2016
- 778
-
Breakthrough therapies in B-cell non-Hodgkin lymphomaCheah, C. Y. / Fowler, N. H. / Wang, M. L. et al. | 2016
- 787
-
Phosphoproteomics in translational research: a sarcoma perspectiveNoujaim, J. / Payne, L. S. / Judson, I. / Jones, R. L. / Huang, P. H. et al. | 2016
- 795
-
Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocolMeric-Bernstam, F. / Brusco, L. / Daniels, M. / Wathoo, C. / Bailey, A. M. / Strong, L. / Shaw, K. / Lu, K. / Qi, Y. / Zhao, H. et al. | 2016
- 801
-
Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancerJones, M. R. / Schrader, K. A. / Shen, Y. / Pleasance, E. / Ch'ng, C. / Dar, N. / Yip, S. / Renouf, D. J. / Schein, J. E. / Mungall, A. J. et al. | 2016
- 806
-
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial†Zdenkowski, N. / Forbes, J. F. / Boyle, F. M. / Kannourakis, G. / Gill, P. G. / Bayliss, E. / Saunders, C. / Della-Fiorentina, S. / Kling, N. / Campbell, I. et al. | 2016
- 812
-
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1)Bonnefoi, H. / Grellety, T. / Tredan, O. / Saghatchian, M. / Dalenc, F. / Mailliez, A. / L'Haridon, T. / Cottu, P. / Abadie-Lacourtoisie, S. / You, B. et al. | 2016
- 818
-
The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysisRusthoven, C. G. / Rabinovitch, R. A. / Jones, B. L. / Koshy, M. / Amini, A. / Yeh, N. / Jackson, M. W. / Fisher, C. M. et al. | 2016
- 828
-
Identifying the potential long-term survivors among breast cancer patients with distant metastasisLee, E. S. / Jung, S. Y. / Kim, J. Y. / Kim, J. J. / Yoo, T. K. / Kim, Y. G. / Lee, K. S. / Kim, E. K. / Min, J. W. et al. | 2016
- 834
-
Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III studyBujko, K. / Wyrwicz, L. / Rutkowski, A. / Malinowska, M. / Pietrzak, L. / Kryński, J. / Michalski, W. / Olędzki, J. / Kuśnierz, J. / Zając, L. et al. | 2016
- 843
-
FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trialsCremolini, C. / Loupakis, F. / Masi, G. / Lonardi, S. / Granetto, C. / Mancini, M. L. / Chiara, S. / Moretto, R. / Rossini, D. / Vitello, S. et al. | 2016
- 850
-
Role of major resection in pulmonary metastasectomy for colorectal cancer in the Spanish prospective multicenter study (GECMP-CCR)Hernández, J. / Molins, L. / Fibla, J. J. / Heras, F. / Embún, R. / Rivas, J. J. et al. | 2016
- 856
-
Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29)†Koeberle, D. / Dufour, J. F. / Demeter, G. / Li, Q. / Ribi, K. / Samaras, P. / Saletti, P. / Roth, A. D. / Horber, D. / Buehlmann, M. et al. | 2016
- 862
-
Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancerJamal-Hanjani, M. / Wilson, G. A. / Horswell, S. / Mitter, R. / Sakarya, O. / Constantin, T. / Salari, R. / Kirkizlar, E. / Sigurjonsson, S. / Pelham, R. et al. | 2016
- 868
-
Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA studyNilsson, S. / Cislo, P. / Sartor, O. / Vogelzang, N. J. / Coleman, R. E. / O'Sullivan, J. M. / Reuning-Scherer, J. / Shan, M. / Zhan, L. / Parker, C. et al. | 2016
- 875
-
Prognostic factors in patients with poor-risk germ-cell tumors: a retrospective analysis of the Indiana University experience from 1990 to 2014†Adra, N. / Althouse, S. K. / Liu, H. / Brames, M. J. / Hanna, N. H. / Einhorn, L. H. / Albany, C. et al. | 2016
- 880
-
A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK)Powles, T. / Brown, J. / Larkin, J. / Jones, R. / Ralph, C. / Hawkins, R. / Chowdhury, S. / Boleti, E. / Bhal, A. / Fife, K. et al. | 2016
- 887
-
Spectrum of clinical and genetic features of patients with inherited platelet disorder with suspected predisposition to hematological malignancies: a nationwide survey in JapanYoshimi, A. / Toya, T. / Nannya, Y. / Takaoka, K. / Kirito, K. / Ito, E. / Nakajima, H. / Hayashi, Y. / Takahashi, T. / Moriya-Saito, A. et al. | 2016
- 895
-
Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab eraCheah, C. Y. / Chihara, D. / Ahmed, M. / Davis, R. E. / Nastoupil, L. J. / Phansalkar, K. / Hagemeister, F. B. / Fayad, L. E. / Westin, J. R. / Oki, Y. et al. | 2016
- 902
-
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myelomaFouquet, G. / Pegourie, B. / Macro, M. / Petillon, M. O. / Karlin, L. / Caillot, D. / Roussel, M. / Arnulf, B. / Mathiot, C. / Marit, G. et al. | 2016
- 908
-
Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancerVillaflor, V. M. / Melotek, J. M. / Karrison, T. G. / Brisson, R. J. / Blair, E. A. / Portugal, L. / De Souza, J. A. / Ginat, D. T. / Stenson, K. M. / Langerman, A. et al. | 2016
- 914
-
Merkel cell carcinoma: value of sentinel lymph-node status and adjuvant radiation therapyServy, A. / Maubec, E. / Sugier, P. E. / Grange, F. / Mansard, S. / Lesimple, T. / Marinho, E. / Couturaud, B. / Girod, A. / Albert, S. et al. | 2016
- 920
-
What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)Drilon, A. / Li, G. / Dogan, S. / Gounder, M. / Shen, R. / Arcila, M. / Wang, L. / Hyman, D. M. / Hechtman, J. / Wei, G. et al. | 2016
- 926
-
The global decrease in cancer mortality: trends and disparitiesHashim, D. / Boffetta, P. / La Vecchia, C. / Rota, M. / Bertuccio, P. / Malvezzi, M. / Negri, E. et al. | 2016
- 933
-
Cancer mortality in cohorts of workers in the European rubber manufacturing industry first employed since 1975Boniol, M. / Koechlin, A. / Świątkowska, B. / Sorahan, T. / Wellmann, J. / Taeger, D. / Jakobsson, K. / Pira, E. / Boffetta, P. / La Vecchia, C. et al. | 2016
- 941
-
Periodontal disease and risk of all cancers among male never smokers: an updated analysis of the Health Professionals Follow-up StudyMichaud, D. S. / Kelsey, K. T. / Papathanasiou, E. / Genco, C. A. / Giovannucci, E. et al. | 2016
- 947
-
A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcomaThomas, S. / Aggarwal, R. / Jahan, T. / Ryan, C. / Troung, T. / Cripps, A. M. / Raha, P. / Thurn, K. T. / Chen, S. / Grabowsky, J. A. et al. | 2016
- 953
-
Ovarian suppression during chemotherapy increases pregnancy rate in survivorsBlumenfeld, Z. et al. | 2016
- 953
-
Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinibTakegawa, N. / Hayashi, H. / Iizuka, N. / Takahama, T. / Ueda, H. / Tanaka, K. / Takeda, M. / Nakagawa, K. et al. | 2016
- 955
-
Prognostic impact of extracapsular lymph node involvement in colorectal cancerHuang, Q. / Qin, X. et al. | 2016
- 955
-
Extranodal extension is an important prognostic parameter for both colonic and rectal cancerLuchini, C. / Nottegar, A. / Pea, A. / Solmi, M. / Stubbs, B. / Capelli, P. / Sergi, G. / Manzato, E. / Fassan, M. / Wood, L. D. et al. | 2016
- 956
-
Prognostic impact of extra-nodal extension on colon and rectal cancer should be investigated separatelyHuang, Q. / Yang, H. et al. | 2016
- 957
-
Reply to the letter to the editor ‘A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma’ by Rosati et al.Hines, R. B. / Al-Rajabi, R. et al. | 2016
- 958
-
Reply to the letter to the editor ‘Number-Needed-To-Treat for pricing costly anti-cancer drugs. The example of Regorafenib in metastatic colorectal cancer’ by Graziano et al.Pignatti, F. / Martinalbo, J. / Jonsson, B. / Foggi, P. et al. | 2016
- 958
-
Dendritic cells stimulated by MUC1 antigen could induce lymphocytes' anergy through PD-L2 but not through PD-L1 patwayWojas-Krawczyk, K. / Homa-Mlak, I. / Krawczyk, P. / Kucharczyk, T. / Milanowski, J. et al. | 2016
- 961
-
Lessons from clinical trials on quality-of-life assessment in ovarian cancer trialsDi Maio, M. / Perrone, F. et al. | 2016
- 962
-
Diagnostic Gleason score and castration-resistant prostate cancerJayaram, A. / Attard, G. et al. | 2016
- 965
-
Risk factors, prevalence, and course of severe fatigue after breast cancer treatment: a meta-analysis involving 12 327 breast cancer survivorsAbrahams, H. J. / Gielissen, M. F. / Schmits, I. C. / Verhagen, C. A. / Rovers, M. M. / Knoop, H. et al. | 2016
- 975
-
Anti-tumour activity of platinum compounds in advanced prostate cancer—a systematic literature reviewHager, S. / Ackermann, C. J. / Joerger, M. / Gillessen, S. / Omlin, A. et al. | 2016
- 984
-
Cancer-associated toll-like receptor modulation and insinuation in infection susceptibility: association or coincidence?Khan, A. A. / Khan, Z. / Warnakulasuriya, S. et al. | 2016
- 998
-
Ocular toxicities of MEK inhibitors and other targeted therapiesStjepanovic, N. / Velazquez-Martin, J. P. / Bedard, P. L. et al. | 2016
- 1006
-
Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1)†Fujiwara, K. / Monk, B. J. / Lhommé, C. / Coleman, R. L. / Brize, A. / Oaknin, A. / Ray-Coquard, I. / Fabbro, M. / Provencher, D. / Bamias, A. et al. | 2016
- 1013
-
Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safetyMatulonis, U. A. / Penson, R. T. / Domchek, S. M. / Kaufman, B. / Shapira-Frommer, R. / Audeh, M. W. / Kaye, S. / Molife, L. R. / Gelmon, K. A. / Robertson, J. D. et al. | 2016
- 1020
-
A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group studyTrédan, O. / Follana, P. / Moullet, I. / Cropet, C. / Trager-Maury, S. / Dauba, J. / Lavau-Denes, S. / Diéras, V. / Béal-Ardisson, D. / Gouttebel, M. et al. | 2016
- 1029
-
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer†Michiels, S. / Pugliano, L. / Marguet, S. / Grun, D. / Barinoff, J. / Cameron, D. / Cobleigh, M. / Di Leo, A. / Johnston, S. / Gasparini, G. et al. | 2016
- 1035
-
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2− early breast cancer: WSG-AGO EC-Doc TrialGluz, O. / Liedtke, C. / Huober, J. / Peyro-Saint-Paul, H. / Kates, R. E. / Kreipe, H. H. / Hartmann, A. / Pelz, E. / Erber, R. / Mohrmann, S. et al. | 2016
- 1041
-
Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trialMackey, J. R. / Pieńkowski, T. / Crown, J. / Sadeghi, S. / Martin, M. / Chan, A. / Saleh, M. / Sehdev, S. / Provencher, L. / Semiglazov, V. et al. | 2016
- 1047
-
Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trialHarbeck, N. / Iyer, S. / Turner, N. / Cristofanilli, M. / Ro, J. / André, F. / Loi, S. / Verma, S. / Iwata, H. / Bhattacharyya, H. et al. | 2016
- 1055
-
Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOXCiardiello, F. / Normanno, N. / Martinelli, E. / Troiani, T. / Pisconti, S. / Cardone, C. / Nappi, A. / Bordonaro, A. R. / Rachiglio, M. / Lambiase, M. et al. | 2016
- 1062
-
Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancerAmatu, A. / Barault, L. / Moutinho, C. / Cassingena, A. / Bencardino, K. / Ghezzi, S. / Palmeri, L. / Bonazzina, E. / Tosi, F. / Ricotta, R. et al. | 2016
- 1068
-
Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials†Overman, M. J. / Morris, V. / Kee, B. / Fogelman, D. / Xiao, L. / Eng, C. / Dasari, A. / Shroff, R. / Mazard, T. / Shaw, K. et al. | 2016
- 1074
-
Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safetyLuo, H. Y. / Li, Y. H. / Wang, W. / Wang, Z. Q. / Yuan, X. / Ma, D. / Wang, F. H. / Zhang, D. S. / Lin, D. R. / Lin, Y. C. et al. | 2016
- 1081
-
Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemiaYoon, J. H. / Yhim, H. Y. / Kwak, J. Y. / Ahn, J. S. / Yang, D. H. / Lee, J. J. / Kim, S. J. / Kim, J. S. / Park, S. J. / Choi, C. W. et al. | 2016
- 1088
-
Reduced intensity allogeneic stem cell transplantation for follicular lymphoma relapsing after an autologous transplant achieves durable long-term disease control: an analysis from the Lymphoma Working Party of the EBMT†Robinson, S. P. / Boumendil, A. / Finel, H. / Schouten, H. / Ehninger, G. / Maertens, J. / Crawley, C. / Rambaldi, A. / Russell, N. / Anders, W. et al. | 2016
- 1095
-
The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study†Alzahrani, M. / El-Galaly, T. C. / Hutchings, M. / Hansen, J. W. / Loft, A. / Johnsen, H. E. / Iyer, V. / Wilson, D. / Sehn, L. H. / Savage, K. J. et al. | 2016
- 1100
-
Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemiaFalchi, L. / Vitale, C. / Keating, M. J. / Lerner, S. / Wang, X. / Elhor Gbito, K. Y. / Strom, S. / Wierda, W. G. / Ferrajoli, A. et al. | 2016
- 1107
-
Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV ‘real life’ trial on the variability of response to opioidsCorli, O. / Floriani, I. / Roberto, A. / Montanari, M. / Galli, F. / Greco, M. T. / Caraceni, A. / Kaasa, S. / Dragani, T. A. / Azzarello, G. et al. | 2016
- 1116
-
A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancersChi, K. N. / Yu, E. Y. / Jacobs, C. / Bazov, J. / Kollmannsberger, C. / Higano, C. S. / Mukherjee, S. D. / Gleave, M. E. / Stewart, P. S. / Hotte, S. J. et al. | 2016
- 1123
-
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomasGaudio, E. / Tarantelli, C. / Kwee, I. / Barassi, C. / Bernasconi, E. / Rinaldi, A. / Ponzoni, M. / Cascione, L. / Targa, A. / Stathis, A. et al. | 2016
- 1129
-
Breast cancer incidence and mortality: trends over 40 years among women in Shanghai, ChinaHuang, Z. / Wen, W. / Zheng, Y. / Gao, Y. T. / Wu, C. / Bao, P. / Wang, C. / Gu, K. / Peng, P. / Gong, Y. et al. | 2016
- 1135
-
Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanomaSpain, L. / Higgins, R. / Gopalakrishnan, K. / Turajlic, S. / Gore, M. / Larkin, J. et al. | 2016
- 1138
-
Targeted treatment and immunotherapy in leptomeningeal metastases from melanomaGeukes Foppen, M. H. / Brandsma, D. / Blank, C. U. / van Thienen, J. V. / Haanen, J. B. / Boogerd, W. et al. | 2016
- 1143
-
Large-scale prospective pharmacogenomics study of oxaliplatin-induced neuropathy in colon cancer patients enrolled in the JFMC41-1001-C2 (JOIN Trial)Kanai, M. / Kawaguchi, T. / Kotaka, M. / Shinozaki, K. / Touyama, T. / Manaka, D. / Ishigure, K. / Hasegawa, J. / Munemoto, Y. / Matsui, T. et al. | 2016
- 1148
-
A genomic case study of mixed fibrolamellar hepatocellular carcinomaGriffith, O. L. / Griffith, M. / Krysiak, K. / Magrini, V. / Ramu, A. / Skidmore, Z. L. / Kunisaki, J. / Austin, R. / McGrath, S. / Zhang, J. et al. | 2016
- 1155
-
Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case studyMorrow, C. J. / Trapani, F. / Metcalf, R. L. / Bertolini, G. / Hodgkinson, C. L. / Khandelwal, G. / Kelly, P. / Galvin, M. / Carter, L. / Simpson, K. L. et al. | 2016
- 1161
-
Rociletinib: has the TIGER lost a few of its stripes?Dhingra, K. et al. | 2016
- 1165
-
Osimertinib (AZD9291)—a science-driven, collaborative approach to rapid drug design and developmentYver, A. et al. | 2016
- 1171
-
What is the clinical impact of the LUX-Lung 5 trial?Addeo, A. et al. | 2016
- 1171
-
Reply to the letter to the editor ‘A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma’ by Hines et al.Rosati, G. / Mosconi, P. / Torri, V. / Apolone, G. / Johnson, F. E. / Fossati, R. et al. | 2016
- 1172
-
Reply to the letter to the editor ‘What is the clinical impact of the LUX-Lung 5 trial?’ by AddeoSchuler, M. / Yang, J. C. / Planchard, D. et al. | 2016
- 1173
-
Reply to the letter to the editor ‘Survival in young adults diagnosed with follicular lymphoma’ by Calvo et al.Conconi, A. / Montoto, S. / Montserrat, E. / Zucca, E. et al. | 2016
- 1174
-
The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanomaLee, B. / Wong, A. / Kee, D. / Neeson, P. / Shackleton, M. / McArthur, G. / Sandhu, S. et al. | 2016
- 1177
-
Reply to the letter to the editor ‘On the tumor risk from dental diagnostic X-ray exposure’ by JarginLin, M. C. / Lee, C. F. / Kao, C. H. et al. | 2016
- 1177
-
On the tumor risk from dental diagnostic X-ray exposureJargin, S. V. et al. | 2016
- 1178
-
Pulmonary sarcoidosis induced by the anti-PD1 monoclonal antibody pembrolizumabCousin, S. / Toulmonde, M. / Kind, M. / Cazeau, A. L. / Bechade, D. / Coindre, J. M. / Italiano, A. et al. | 2016
- 1180
-
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancerO'Neil, B. H. / Scott, A. J. / Ma, W. W. / Cohen, S. J. / Aisner, D. L. / Menter, A. R. / Tejani, M. A. / Cho, J. K. / Granfortuna, J. / Coveler, A. L. et al. | 2016
- 1181
-
Breast cancer genetic risk profile is differentially associated with interval and screen-detected breast cancersLi, J. / Holm, J. / Bergh, J. / Eriksson, M. / Darabi, H. / Lindström, L. S. / Törnberg, S. / Hall, P. / Czene, K. et al. | 2016
- 1183
-
A tribute to the life and career of Holbrook KohrtMarabelle, A. / Houot, R. et al. | 2016
- 1185
-
Statistical controversies in clinical research: the importance of importanceGleiss, A. / Zeillinger, R. / Braicu, E. I. / Trillsch, F. / Vergote, I. / Schemper, M. et al. | 2016
- 1190
-
Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapiesSanmamed, M. F. / Chester, C. / Melero, I. / Kohrt, H. et al. | 2016
- 1199
-
Biomarkers associated with checkpoint inhibitorsManson, G. / Norwood, J. / Marabelle, A. / Kohrt, H. / Houot, R. et al. | 2016
- 1207
-
CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)—Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)Schmidt-Hieber, M. / Silling, G. / Schalk, E. / Heinz, W. / Panse, J. / Penack, O. / Christopeit, M. / Buchheidt, D. / Meyding-Lamadé, U. / Hähnel, S. et al. | 2016
- 1226
-
Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomasRuan, J. / Shah, B. / Martin, P. / Schuster, S. J. et al. | 2016
- 1235
-
Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study†Jacot, W. / Firmin, N. / Roca, L. / Topart, D. / Gallet, S. / Durigova, A. / Mirr, S. / Abach, L. / Pouderoux, S. / D'Hondt, V. et al. | 2016
- 1241
-
Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrenceMittendorf, E. A. / Ardavanis, A. / Symanowski, J. / Murray, J. L. / Shumway, N. M. / Litton, J. K. / Hale, D. F. / Perez, S. A. / Anastasopoulou, E. A. / Pistamaltzian, N. F. et al. | 2016
- 1249
-
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study†Martin, M. / Fumoleau, P. / Dewar, J. A. / Albanell, J. / Limentani, S. A. / Campone, M. / Chang, J. C. / Patre, M. / Strasak, A. / de Haas, S. L. et al. | 2016
- 1257
-
Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcomaMatsuo, K. / Takazawa, Y. / Ross, M. S. / Elishaev, E. / Podzielinski, I. / Yunokawa, M. / Sheridan, T. B. / Bush, S. H. / Klobocista, M. M. / Blake, E. A. et al. | 2016
- 1266
-
A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC)Oki, E. / Murata, A. / Yoshida, K. / Maeda, K. / Ikejiri, K. / Munemoto, Y. / Sasaki, K. / Matsuda, C. / Kotake, M. / Suenaga, T. et al. | 2016
- 1273
-
Oxaliplatin and 5-FU/folinic acid (modified FOLFOX6) with or without aflibercept in first-line treatment of patients with metastatic colorectal cancer: the AFFIRM studyFolprecht, G. / Pericay, C. / Saunders, M. P. / Thomas, A. / Lopez Lopez, R. / Roh, J. K. / Chistyakov, V. / Höhler, T. / Kim, J. S. / Hofheinz, R. D. et al. | 2016
- 1280
-
Pemetrexed plus carboplatin versus pemetrexed in pretreated patients with advanced non-squamous non-small-cell lung cancer: treating the right patients based on individualized treatment effect prediction†van Kruijsdijk, R. C. / Visseren, F. L. / Boni, L. / Groen, H. J. / Dingemans, A. M. / Aerts, J. G. / van der Graaf, Y. / Ardizzoni, A. / Smit, E. F. et al. | 2016
- 1286
-
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancersDrilon, A. / Bergagnini, I. / Delasos, L. / Sabari, J. / Woo, K. M. / Plodkowski, A. / Wang, L. / Hellmann, M. D. / Joubert, P. / Sima, C. S. et al. | 2016
- 1291
-
Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancerChatterjee, M. / Turner, D. C. / Felip, E. / Lena, H. / Cappuzzo, F. / Horn, L. / Garon, E. B. / Hui, R. / Arkenau, H. T. / Gubens, M. A. et al. | 2016
- 1299
-
Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA)Tandstad, T. / Ståhl, O. / Dahl, O. / Haugnes, H. S. / Håkansson, U. / Karlsdottir, . / Kjellman, A. / Langberg, C. W. / Laurell, A. / Oldenburg, J. et al. | 2016
- 1304
-
Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)–tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinomaNadal, R. / Amin, A. / Geynisman, D. M. / Voss, M. H. / Weinstock, M. / Doyle, J. / Zhang, Z. / Viudez, A. / Plimack, E. R. / McDermott, D. F. et al. | 2016
- 1311
-
Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatmentPouessel, D. / Neuzillet, Y. / Mertens, L. S. / van der Heijden, M. S. / de Jong, J. / Sanders, J. / Peters, D. / Leroy, K. / Manceau, A. / Maille, P. et al. | 2016
- 1317
-
Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomesCheah, C. Y. / Chihara, D. / Horowitz, S. / Sevin, A. / Oki, Y. / Zhou, S. / Fowler, N. H. / Romaguera, J. E. / Turturro, F. / Hagemeister, F. B. et al. | 2016
- 1323
-
Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHLKoch, K. / Hoster, E. / Ziepert, M. / Unterhalt, M. / Ott, G. / Rosenwald, A. / Hansmann, M. L. / Bernd, W. / Stein, H. / Pöschel, V. et al. | 2016
- 1329
-
Oral health and risk of colorectal cancer: results from three cohort studies and a meta-analysisRen, H. G. / Luu, H. N. / Cai, H. / Xiang, Y. B. / Steinwandel, M. / Gao, Y. T. / Hargreaves, M. / Zheng, W. / Blot, W. J. / Long, J. R. et al. | 2016
- 1336
-
Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classesChung, J. H. / Sanford, E. / Johnson, A. / Klempner, S. J. / Schrock, A. B. / Palma, N. A. / Erlich, R. L. / Frampton, G. M. / Chalmers, Z. R. / Vergilio, J. et al. | 2016
- 1342
-
Pragmatic randomized clinical trials: a proposal to enhance evaluation of new cancer therapies with early signs of exceptional activityKoehler, M. / Donnelly, E. T. / Kalanovic, D. / Dagher, R. / Rothenberg, M. L. et al. | 2016
- 1349
-
Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSAHouot, R. / Soussain, C. / Tilly, H. / Haioun, C. / Thieblemont, C. / Casasnovas, O. / Bouabdallah, K. / Morschhauser, F. / Le Gouill, S. / Salles, G. A. et al. | 2016
- 1351
-
Insertion of central venous catheters (CVCs): any changes in the past 10 years?Biffi, R. / Bertoglio, S. / Pittiruti, M. et al. | 2016
- 1351
-
Reply to the letter to the editor ‘Insertion of central venous catheters (CVCs): any changes in the past ten years’ by Biffi et al.Pinto, D. / Gouveia, P. / Sousa, B. / Hutka, M. / Furlanetto, J. / Mariz, J. M. / Wuerstlein, R. / Cardoso, F. et al. | 2016
- 1352
-
Pembrolizumab-induced necrotic myositis in a patient with metastatic melanomaVallet, H. / Gaillet, A. / Weiss, N. / Vanhaecke, C. / Saheb, S. / Touitou, V. / Franck, N. / Kramkimel, N. / Borden, A. / Touat, M. et al. | 2016
- 1353
-
Safety of the PD-1 antibody pembrolizumab in patients with high-grade adverse events under ipilimumab treatment†Bender, C. / Dimitrakopoulou-Strauss, A. / Enk, A. / Hassel, J. C. et al. | 2016
- 1354
-
Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastasesKanai, O. / Fujita, K. / Okamura, M. / Nakatani, K. / Mio, T. et al. | 2016
- 1356
-
Activity of immune checkpoint inhibition in platinum refractory germ-cell tumorsZschäbitz, S. / Lasitschka, F. / Jäger, D. / Grüllich, C. et al. | 2016
- 1360
-
Abandoning diesel because of health perspectives: are there reasonable alternatives?Vreugdenhil, G. / Mannaerts, H. F. et al. | 2016
- 1361
-
Reply to the letter to the editor ‘Abandoning diesel because of health perspectives: are there reasonable alternatives?’ by Vreugdenhil and MannaertsSwanton, C. / Boffetta, P. / Peston, R. / Soria, J. C. et al. | 2016
- 1362
-
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodiesNaidoo, J. / Page, D. B. / Li, B. T. / Connell, L. C. / Schindler, K. / Lacouture, M. E. / Postow, M. A. / Wolchok, J. D. et al. | 2016
- 1365
-
Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?Rustin, G. J. / Hall, M. R. et al. | 2016
- 1366
-
Prognostic pathways in early-stage ovarian cancer: can gene expression transcend histological subtype?McNeish, I. A. et al. | 2016
- 1368
-
PIK3CA mutations in HER2-positive breast cancer: an ongoing conundrumGoel, S. / Krop, I. E. et al. | 2016
- 1372
-
A tribute to biologics in advanced colorectal cancer treatmentSobrero, A. et al. | 2016
- 1374
-
Necitumumab in squamous non-small-cell lung cancer: how to move forward?Garrido, P. / Palacios, J. et al. | 2016
- 1376
-
Where next in kidney cancer?Powles, T. et al. | 2016
- 1378
-
ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology—edition 2016Dittrich, C. / Kosty, M. / Jezdic, S. / Pyle, D. / Berardi, R. / Bergh, J. / El Saghir, N. / Lotz, J. P. / Österlund, P. / Pavlidis, N. et al. | 2016
- 1382
-
International cancer seminars: a focus on kidney cancerScelo, G. / Hofmann, J. N. / Banks, R. E. / Bigot, P. / Bhatt, R. S. / Cancel-Tassin, G. / Chew, S. K. / Creighton, C. J. / Cussenot, O. / Davis, I. J. et al. | 2016
- 1386
-
ESMO consensus guidelines for the management of patients with metastatic colorectal cancerVan Cutsem, E. / Cervantes, A. / Adam, R. / Sobrero, A. / Van Krieken, J. H. / Aderka, D. / Aranda Aguilar, E. / Bardelli, A. / Benson, A. / Bodoky, G. et al. | 2016
- 1423
-
ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in EuropeCherny, N. / Sullivan, R. / Torode, J. / Saar, M. / Eniu, A. et al. | 2016
- 1443
-
Consensus on precision medicine for metastatic cancers: a report from the MAP conferenceSwanton, C. / Soria, J. C. / Bardelli, A. / Biankin, A. / Caldas, C. / Chandarlapaty, S. / de Koning, L. / Dive, C. / Feunteun, J. / Leung, S. Y. et al. | 2016
- 1449
-
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancerMoschetta, M. / George, A. / Kaye, S. B. / Banerjee, S. et al. | 2016
- 1456
-
Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratorySartore-Bianchi, A. / Loupakis, F. / Argilés, G. / Prager, G. W. et al. | 2016
- 1467
-
The impact of the revolution in hepatitis C treatment on hepatocellular carcinomaWirth, T. C. / Manns, M. P. et al. | 2016
- 1474
-
Current management of newly diagnosed acute promyelocytic leukemiaCicconi, L. / Lo-Coco, F. et al. | 2016
- 1482
-
Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapyPitt, J. M. / Marabelle, A. / Eggermont, A. / Soria, J. C. / Kroemer, G. / Zitvogel, L. et al. | 2016
- 1492
-
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)Kim, J. M. / Chen, D. S. et al. | 2016
- 1505
-
Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trialLindemann, K. / Kristensen, G. / Mirza, M. R. / Davies, L. / Hilpert, F. / Romero, I. / Ayhan, A. / Burges, A. / Rubio, M. J. / Raspagliesi, F. et al. | 2016
- 1511
-
A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessmentCalura, E. / Paracchini, L. / Fruscio, R. / DiFeo, A. / Ravaggi, A. / Peronne, J. / Martini, P. / Sales, G. / Beltrame, L. / Bignotti, E. et al. | 2016
- 1519
-
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab†Loibl, S. / Majewski, I. / Guarneri, V. / Nekljudova, V. / Holmes, E. / Bria, E. / Denkert, C. / Schem, C. / Sotiriou, C. / Loi, S. et al. | 2016
- 1525
-
Pooled analyses of eribulin in metastatic breast cancer patients with at least one prior chemotherapyPivot, X. / Marmé, F. / Koenigsberg, R. / Guo, M. / Berrak, E. / Wolfer, A. et al. | 2016
- 1532
-
Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somaticWinter, C. / Nilsson, M. P. / Olsson, E. / George, A. M. / Chen, Y. / Kvist, A. / Törngren, T. / Vallon-Christersson, J. / Hegardt, C. / Häkkinen, J. et al. | 2016
- 1539
-
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)Yamazaki, K. / Nagase, M. / Tamagawa, H. / Ueda, S. / Tamura, T. / Murata, K. / Eguchi Nakajima, T. / Baba, E. / Tsuda, M. / Moriwaki, T. et al. | 2016
- 1546
-
P21-activated kinase 1 (Pak1) signaling influences therapeutic outcome in pancreatic cancerJagadeeshan, S. / Subramanian, A. / Tentu, S. / Beesetti, S. / Singhal, M. / Raghavan, S. / Surabhi, R. P. / Mavuluri, J. / Bhoopalan, H. / Biswal, J. et al. | 2016
- 1557
-
PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancerSclafani, F. / Brown, G. / Cunningham, D. / Wotherspoon, A. / Tait, D. / Peckitt, C. / Evans, J. / Yu, S. / Sena Teixeira Mendes, L. / Tabernero, J. et al. | 2016
- 1565
-
CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)†Michl, M. / Stintzing, S. / Fischer von Weikersthal, L. / Decker, T. / Kiani, A. / Vehling-Kaiser, U. / Al-Batran, S. E. / Heintges, T. / Lerchenmueller, C. / Kahl, C. et al. | 2016
- 1573
-
Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancerPaz-Ares, L. / Socinski, M. A. / Shahidi, J. / Hozak, R. R. / Soldatenkova, V. / Kurek, R. / Varella-Garcia, M. / Thatcher, N. / Hirsch, F. R. et al. | 2016
- 1579
-
Efficacy of the nanoparticle–drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I–IIa clinical trialKeefe, S. M. / Hoffman-Censits, J. / Cohen, R. B. / Mamtani, R. / Heitjan, D. / Eliasof, S. / Nixon, A. / Turnbull, B. / Garmey, E. G. / Gunnarsson, O. et al. | 2016
- 1585
-
Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial†Clement, P. M. / Gauler, T. / Machiels, J. P. / Haddad, R. I. / Fayette, J. / Licitra, L. F. / Tahara, M. / Cohen, E. E. / Cupissol, D. / Grau, J. J. et al. | 2016
- 1594
-
Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer†Argiris, A. / Bauman, J. E. / Ohr, J. / Gooding, W. E. / Heron, D. E. / Duvvuri, U. / Kubicek, G. J. / Posluszny, D. M. / Vassilakopoulou, M. / Kim, S. et al. | 2016
- 1601
-
Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE studySuzuki, K. / Yamanaka, T. / Hashimoto, H. / Shimada, Y. / Arata, K. / Matsui, R. / Goto, K. / Takiguchi, T. / Ohyanagi, F. / Kogure, Y. et al. | 2016
- 1607
-
Factors associated with depression and anxiety symptoms in family caregivers of patients with incurable cancer†Nipp, R. D. / El-Jawahri, A. / Fishbein, J. N. / Gallagher, E. R. / Stagl, J. M. / Park, E. R. / Jackson, V. A. / Pirl, W. F. / Greer, J. A. / Temel, J. S. et al. | 2016
- 1612
-
Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patientsPatel, J. D. / Pereira, J. R. / Chen, J. / Liu, J. / Guba, S. C. / John, W. J. / Orlando, M. / Scagliotti, G. / Bonomi, P. D. et al. | 2016
- 1619
-
The role of oral hygiene in head and neck cancer: results from International Head and Neck Cancer Epidemiology (INHANCE) consortiumHashim, D. / Sartori, S. / Brennan, P. / Curado, M. P. / Wünsch-Filho, V. / Divaris, K. / Olshan, A. F. / Zevallos, J. P. / Winn, D. M. / Franceschi, S. et al. | 2016
- 1625
-
Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial†Eigentler, T. K. / Gutzmer, R. / Hauschild, A. / Heinzerling, L. / Schadendorf, D. / Nashan, D. / Hölzle, E. / Kiecker, F. / Becker, J. / Sunderkötter, C. et al. | 2016
- 1633
-
How to report toxicity associated with targeted therapies?Cabarrou, B. / Boher, J. M. / Bogart, E. / Tresch-Bruneel, E. / Penel, N. / Ravaud, A. / Escudier, B. / Mahier Ait-Oukhatar, C. / Delord, J. P. / Roché, H. et al. | 2016
- 1638
-
The time to progression ratio: a new individualized volumetric parameter for the early detection of clinical benefit of targeted therapiesCirkel, G. A. / Weeber, F. / Bins, S. / Gadellaa-van Hooijdonk, C. G. / van Werkhoven, E. / Willems, S. M. / van Stralen, M. / Veldhuis, W. B. / Ubink, I. / Steeghs, N. et al. | 2016
- 1644
-
Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathwaysDoherty, M. / Metcalfe, T. / Guardino, E. / Peters, E. / Ramage, L. et al. | 2016
- 1647
-
Significance of the prognostic stratification of extranodal extension in colorectal cancerLuchini, C. / Nottegar, A. / Pea, A. / Solmi, M. / Stubbs, B. / Capelli, P. / Sergi, G. / Manzato, E. / Fassan, M. / Wood, L. D. et al. | 2016
- 1647
-
Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baselineRamanathan, R. K. / Korn, R. L. / Chiorean, E. G. / Liu, H. / Von Hoff, D. D. et al. | 2016
- 1648
-
The challenge to one-course carboplatin in seminoma clinical stage 1Dieckmann, K. P. / Anheuser, P. et al. | 2016
- 1649
-
Anti-PD-1-associated organizing pneumonia in a responding melanoma patientFiset, P. O. / Shapera, S. / Butler, M. O. / Tsao, M. S. et al. | 2016
- 1650
-
Pulmonary sarcoidosis induced by the anti-PD-1 monoclonal antibody pembrolizumab or post-immunotherapy granulomatous reaction: which is more appropriate terminology?Paydas, S. et al. | 2016
- 1651
-
Benefit of therapeutic drug monitoring to disclose pharmacokinetic interaction between sunitinib and calcium channel blockerDa Silva, F. / Thomas-Schoemann, A. / Huillard, O. / Goldwasser, F. / Blanchet, B. et al. | 2016
- 1652
-
Reply to ‘Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents’ by Saad and Buysevan Halteren, H. K. et al. | 2016
- 1653
-
Response to the letter to the editor ‘Reply to “Statistical controversies in clinical research: end points other than survival are vital for regulatory approval of anticancer agents” by H. K. van Halteren’Saad, E. D. / Buyse, M. et al. | 2016
- 1655
-
New goalsSoria, J. C. et al. | 2016
- 1656
-
Saving the best treatment for last?Coleman, R. L. / Monk, B. J. et al. | 2016
- 1658
-
PD-L1 expression in penile cancer: a new frontier for immune checkpoint inhibitors?Al-Ahmadie, H. et al. | 2016
- 1660
-
Communication in oncology: now we train - but how well?†Stiefel, F. / Bourquin, C. et al. | 2016
- 1664
-
Cervical esophageal cancer: a gap in cancer knowledgeHoeben, A. / Polak, J. / Van De Voorde, L. / Hoebers, F. / Grabsch, H. I. / de Vos-Geelen, J. et al. | 2016
- 1675
-
The promise of immunotherapy in head and neck squamous cell carcinomaEconomopoulou, P. / Agelaki, S. / Perisanidis, C. / Giotakis, E. I. / Psyrri, A. et al. | 2016
- 1685
-
Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspectiveShenoy, N. / Pagliaro, L. et al. | 2016
- 1696
-
The forgotten woman's cancer: vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapyClancy, A. A. / Spaans, J. N. / Weberpals, J. I. et al. | 2016
- 1706
-
Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approachesUdager, A. M. / Liu, T. Y. / Skala, S. L. / Magers, M. J. / McDaniel, A. S. / Spratt, D. E. / Feng, F. Y. / Siddiqui, J. / Cao, X. / Fields, K. L. et al. | 2016
- 1712
-
A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancerLacouture, M. E. / Keefe, D. M. / Sonis, S. / Jatoi, A. / Gernhardt, D. / Wang, T. / Doherty, J. P. / Giri, N. / Nadanaciva, S. / O'Connell, J. et al. | 2016
- 1719
-
Safety of everolimus plus exemestane in patients with hormone-receptor–positive, HER2–negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)Jerusalem, G. / Mariani, G. / Ciruelos, E. M. / Martin, M. / Tjan-Heijnen, V. C. / Neven, P. / Gavila, J. G. / Michelotti, A. / Montemurro, F. / Generali, D. et al. | 2016
- 1725
-
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational studyDelaloge, S. / Pérol, D. / Courtinard, C. / Brain, E. / Asselain, B. / Bachelot, T. / Debled, M. / Dieras, V. / Campone, M. / Levy, C. et al. | 2016
- 1733
-
Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trialTrillsch, F. / Mahner, S. / Hilpert, F. / Davies, L. / García-Martínez, E. / Kristensen, G. / Savarese, A. / Vuylsteke, P. / Los, M. / Zagouri, F. et al. | 2016
- 1740
-
Long-term significance of urinary neopterin in ovarian cancer: a study by the Austrian Association for Gynecologic Oncology (AGO)Volgger, B. M. / Windbichler, G. H. / Zeimet, A. G. / Graf, A. H. / Bogner, G. / Angleitner-Boubenizek, L. / Rohde, M. / Denison, U. / Sliutz, G. / Fuith, L. C. et al. | 2016
- 1746
-
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study groupModest, D. P. / Ricard, I. / Heinemann, V. / Hegewisch-Becker, S. / Schmiegel, W. / Porschen, R. / Stintzing, S. / Graeven, U. / Arnold, D. / von Weikersthal, L. F. et al. | 2016
- 1754
-
Stepped care targeting psychological distress in head and neck cancer and lung cancer patients: a randomized, controlled trialKrebber, A. M. / Jansen, F. / Witte, B. I. / Cuijpers, P. / de Bree, R. / Becker-Commissaris, A. / Smit, E. F. / van Straten, A. / Eeckhout, A. M. / Beekman, A. T. et al. | 2016
- 1761
-
Fatigue in people with localized colorectal cancer who do and do not receive chemotherapy: a longitudinal prospective studyVardy, J. L. / Dhillon, H. M. / Pond, G. R. / Renton, C. / Dodd, A. / Zhang, H. / Clarke, S. J. / Tannock, I. F. et al. | 2016
- 1768
-
Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countriesKleijnen, S. / Lipska, I. / Leonardo Alves, T. / Meijboom, K. / Elsada, A. / Vervölgyi, V. / d'Andon, A. / Timoney, A. / Leufkens, H. G. / De Boer, A. et al. | 2016
- 1776
-
To be in pain (or not): a computer enables outpatients to inform their physicianOldenmenger, W. H. / Witkamp, F. E. / Bromberg, J. E. / Jongen, J. L. / Lieverse, P. J. / Huygen, F. J. / Baan, M. A. / van Zuylen, L. / van der Rijt, C. C. et al. | 2016
- 1782
-
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma†Simonelli, M. / Zucali, P. / Santoro, A. / Thomas, M. B. / de Braud, F. G. / Borghaei, H. / Berlin, J. / Denlinger, C. S. / Noberasco, C. / Rimassa, L. et al. | 2016
- 1788
-
Identification of genetic variants in pharmacokinetic genes associated with Ewing Sarcoma treatment outcomeRuiz-Pinto, S. / Pita, G. / Patiño-García, A. / García-Miguel, P. / Alonso, J. / Pérez-Martínez, A. / Sastre, A. / Gómez-Mariano, G. / Lissat, A. / Scotlandi, K. et al. | 2016
- 1794
-
Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapyBen-Ami, E. / Barysauskas, C. M. / von Mehren, M. / Heinrich, M. C. / Corless, C. L. / Butrynski, J. E. / Morgan, J. A. / Wagner, A. J. / Choy, E. / Yap, J. T. et al. | 2016
- 1799
-
Inclusion of elderly patients in oncology clinical trialsLe Saux, O. / Falandry, C. / Gan, H. K. / You, B. / Freyer, G. / Péron, J. et al. | 2016
- 1805
-
Oncolytic immunotherapy: an emerging new modality for the treatment of cancerCoffin, R. S. et al. | 2016
- 1809
-
Reply to ‘The challenge to one course carboplatin in seminoma clinical stage 1’ by Dieckmann and AnheuserTandstad, T. / Cohn-Cedermark, G. et al. | 2016
- 1810
-
Reply to ‘Safety profile of capecitabine as maintenance treatment after XELOX or FOLFOX in metastatic colorectal cancer patients’ by C. Cremolini et al.Luo, H. Y. / Xu, R. H. et al. | 2016
- 1810
-
Safety profile of capecitabine as maintenance treatment after induction with XELOX or FOLFOX in metastatic colorectal cancer patientsCremolini, C. / Moretto, R. / Masi, G. / Falcone, A. et al. | 2016
- 1811
-
Histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma (ENKTL)Tan, D. / Diong, C. P. / Loh, Y. / Goh, Y. T. et al. | 2016
- 1812
-
Challenging the soaring price of cancer medicines: a call for equity and transparencyGonçalves, A. / Maraninchi, D. / Vernant, J. P. et al. | 2016
- 1813
-
Successful treatment of refractory leiomyosarcoma with the PD-1 inhibitor nivolumabHeine, A. / Kristiansen, G. / Schild, H. H. / Brossart, P. et al. | 2016
- 1815
-
Searching for aurora in the night of sarcoma phase II trials: isn't it time to move to second gear?Toulmonde, M. et al. | 2016
- 1818
-
Impact of thoracic radiotherapy timing in limited-stage small-cell lung cancer: usefulness of the individual patient data meta-analysis†De Ruysscher, D. / Lueza, B. / Le Péchoux, C. / Johnson, D. H. / O'Brien, M. / Murray, N. / Spiro, S. / Wang, X. / Takada, M. / Lebeau, B. et al. | 2016
- 1829
-
Chemotherapy remains an essential element of personalized care for persons with lung cancersHellmann, M. D. / Li, B. T. / Chaft, J. E. / Kris, M. G. et al. | 2016
- 1836
-
Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysisMei, Z. B. / Duan, C. Y. / Li, C. B. / Cui, L. / Ogino, S. et al. | 2016
- 1848
-
Best practice guidelines in the psychosocial management of HPV-related head and neck cancer: recommendations from the European Head and Neck Cancer Society's Make Sense CampaignReich, M. / Licitra, L. / Vermorken, J. B. / Bernier, J. / Parmar, S. / Golusinski, W. / Castellsagué, X. / Leemans, C. R. et al. | 2016
- 1855
-
Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma†Dickson, M. A. / Mahoney, M. R. / Tap, W. D. / D'Angelo, S. P. / Keohan, M. L. / Van Tine, B. A. / Agulnik, M. / Horvath, L. E. / Nair, J. S. / Schwartz, G. K. et al. | 2016
- 1860
-
Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancersFumagalli, D. / Wilson, T. R. / Salgado, R. / Lu, X. / Yu, J. / O'Brien, C. / Walter, K. / Huw, L. Y. / Criscitiello, C. / Laios, I. et al. | 2016
- 1867
-
Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trialDieci, M. V. / Prat, A. / Tagliafico, E. / Paré, L. / Ficarra, G. / Bisagni, G. / Piacentini, F. / Generali, D. G. / Conte, P. / Guarneri, V. et al. | 2016
- 1873
-
Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)Mavroudis, D. / Matikas, A. / Malamos, N. / Papakotoulas, P. / Kakolyris, S. / Boukovinas, I. / Athanasiadis, A. / Kentepozidis, N. / Ziras, N. / Katsaounis, P. et al. | 2016
- 1879
-
Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancerImaoka, H. / Toiyama, Y. / Fujikawa, H. / Hiro, J. / Saigusa, S. / Tanaka, K. / Inoue, Y. / Mohri, Y. / Mori, T. / Kato, T. et al. | 2016
- 1887
-
Improved survival with dose-escalated radiotherapy in stage III non-small-cell lung cancer: analysis of the National Cancer DatabaseBrower, J. V. / Amini, A. / Chen, S. / Hullett, C. R. / Kimple, R. J. / Wojcieszynski, A. P. / Bassetti, M. / Witek, M. E. / Yu, M. / Harari, P. M. et al. | 2016
- 1895
-
Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)†Joerger, M. / von Pawel, J. / Kraff, S. / Fischer, J. R. / Eberhardt, W. / Gauler, T. C. / Mueller, L. / Reinmuth, N. / Reck, M. / Kimmich, M. et al. | 2016
- 1902
-
A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinomaHo, A. L. / Dunn, L. / Sherman, E. J. / Fury, M. G. / Baxi, S. S. / Chandramohan, R. / Dogan, S. / Morris, L. G. / Cullen, G. D. / Haque, S. et al. | 2016
- 1909
-
Is it best to expect the worst? Influence of patients' side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort studyNestoriuc, Y. / von Blanckenburg, P. / Schuricht, F. / Barsky, A. J. / Hadji, P. / Albert, U. S. / Rief, W. et al. | 2016
- 1916
-
A randomized trial on chlorhexidine dressings for the prevention of catheter-related bloodstream infections in neutropenic patientsBiehl, L. M. / Huth, A. / Panse, J. / Krämer, C. / Hentrich, M. / Engelhardt, M. / Schäfer-Eckart, K. / Kofla, G. / Kiehl, M. / Wendtner, C. M. et al. | 2016
- 1922
-
Selection of an early biomarker for vascular normalization using dynamic contrast-enhanced ultrasonography to predict outcomes of metastatic patients treated with bevacizumabLassau, N. / Coiffier, B. / Kind, M. / Vilgrain, V. / Lacroix, J. / Cuinet, M. / Taieb, S. / Aziza, R. / Sarran, A. / Labbe-Devilliers, C. et al. | 2016
- 1928
-
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomasPatnaik, A. / Appleman, L. J. / Tolcher, A. W. / Papadopoulos, K. P. / Beeram, M. / Rasco, D. W. / Weiss, G. J. / Sachdev, J. C. / Chadha, M. / Fulk, M. et al. | 2016
- 1940
-
Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 studyLong, G. V. / Atkinson, V. / Ascierto, P. A. / Robert, C. / Hassel, J. C. / Rutkowski, P. / Savage, K. J. / Taylor, F. / Coon, C. / Gilloteau, I. et al. | 2016
- 1947
-
Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT)Saiag, P. / Gutzmer, R. / Ascierto, P. A. / Maio, M. / Grob, J. J. / Murawa, P. / Dreno, B. / Ross, M. / Weber, J. / Hauschild, A. et al. | 2016
- 1953
-
Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancerMansfield, A. S. / Aubry, M. C. / Moser, J. C. / Harrington, S. M. / Dronca, R. S. / Park, S. S. / Dong, H. et al. | 2016
- 1959
-
Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNAGremel, G. / Lee, R. J. / Girotti, M. R. / Mandal, A. K. / Valpione, S. / Garner, G. / Ayub, M. / Wood, S. / Rothwell, D. G. / Fusi, A. et al. | 2016
- 1966
-
Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapyNovotny, J. F. / Cogswell, J. / Inzunza, H. / Harbison, C. / Horak, C. / Averbuch, S. et al. | 2016
- 1970
-
Chemoprevention of hepatocellular carcinoma in people affected by hepatitis C virus: what changes does the introduction of direct-acting antiviral agents make?Testino, G. / Leone, S. et al. | 2016
- 1971
-
Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trialFrüh, M. / Ris, H. B. / Xyrafas, A. / Peters, S. / Mirimanoff, R. O. / Gautschi, O. / Pless, M. / Stupp, R. et al. | 2016
- 1971
-
Reply to ‘Chemoprevention of hepatocellular carcinoma in people affected by hepatitis C virus: what changes does the introduction of direct-acting antiviral agents make?’Wirth, T. C. / Manns, M. P. et al. | 2016
- 1973
-
Is radical chemo-radiotherapy appropriate in patients with stage IV non-small-cell lung cancer due to cervical lymph node metastases?de Boer, P. / Senan, S. et al. | 2016
- 1974
-
The clinical dilemma of grade 3 follicular lymphomaSorigue, M. / Ribera, J. M. / Sancho, J. M. et al. | 2016
- 1974
-
Pulmonary sarcoidosis or post-immunotherapy granulomatous reaction induced by the anti-PD-1 monoclonal antibody pembrolizumab: the terminology is not the key pointCousin, S. / Italiano, A. et al. | 2016
- 1975
-
Ipilimumab-related hypophysitis may precede severe CNS immune attackKöessler, T. / Olivier, T. / Fertani, S. / Marinari, E. / Dutoit, V. / Dietrich, P. Y. et al. | 2016
- 1977
-
Ovarian cancer mortality trends: which factors are involved?Weiderpass, E. / Botteri, E. et al. | 2016
- 1978
-
The role of opioids in cancer progression: emerging experimental and clinical implicationsSjøgren, P. / Kaasa, S. et al. | 2016
- 1981
-
Statistical controversies in clinical research: should schedules of tumor size assessments be changed?Filleron, T. / Kouokam, W. / Gilhodes, J. / Duhamel, A. / Penel, N. / Joly, F. / Tresch-Bruneel, E. / Kramar, A. / Houédé, N. et al. | 2016
- 1988
-
The obese endometrial cancer patient: how do we effectively improve morbidity and mortality in this patient population?Papatla, K. / Huang, M. / Slomovitz, B. et al. | 2016
- 1994
-
Fertility-sparing surgery in epithelial ovarian cancer: a systematic review of oncological issuesBentivegna, E. / Gouy, S. / Maulard, A. / Pautier, P. / Leary, A. / Colombo, N. / Morice, P. et al. | 2016
- 2004
-
Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscapeOlaussen, K. A. / Postel-Vinay, S. et al. | 2016
- 2017
-
Global trends and predictions in ovarian cancer mortalityMalvezzi, M. / Carioli, G. / Rodriguez, T. / Negri, E. / La Vecchia, C. et al. | 2016
- 2025
-
No ‘cure’ within 12 years of diagnosis among breast cancer patients who are diagnosed via mammographic screening: women diagnosed in the West Midlands region of England 1989–2011Woods, L. M. / Morris, M. / Rachet, B. et al. | 2016
- 2032
-
Treatment with methylnaltrexone is associated with increased survival in patients with advanced cancerJanku, F. / Johnson, L. K. / Karp, D. D. / Atkins, J. T. / Singleton, P. A. / Moss, J. et al. | 2016
- 2039
-
Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study)Aapro, M. / Ludwig, H. / Bokemeyer, C. / Gascón, P. / Boccadoro, M. / Denhaerynck, K. / Krendyukov, A. / Gorray, M. / MacDonald, K. / Abraham, I. et al. | 2016
- 2046
-
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancerVrdoljak, E. / Marschner, N. / Zielinski, C. / Gligorov, J. / Cortes, J. / Puglisi, F. / Aapro, M. / Fallowfield, L. / Fontana, A. / Inbar, M. et al. | 2016
- 2053
-
Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN studyFurlanetto, J. / Eiermann, W. / Marmé, F. / Reimer, T. / Reinisch, M. / Schmatloch, S. / Stickeler, E. / Thomssen, C. / Untch, M. / Denkert, C. et al. | 2016
- 2059
-
Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY studyVuylsteke, P. / Huizing, M. / Petrakova, K. / Roylance, R. / Laing, R. / Chan, S. / Abell, F. / Gendreau, S. / Rooney, I. / Apt, D. et al. | 2016
- 2067
-
Tumor-related leukocytosis is associated with poor radiation response and clinical outcome in uterine cervical cancer patientsCho, Y. / Kim, K. H. / Yoon, H. I. / Kim, G. E. / Kim, Y. B. et al. | 2016
- 2074
-
Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trial†Lonardi, S. / Sobrero, A. / Rosati, G. / Di Bartolomeo, M. / Ronzoni, M. / Aprile, G. / Scartozzi, M. / Banzi, M. / Zampino, M. G. / Pasini, F. et al. | 2016
- 2082
-
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression†Obermannová, R. / Van Cutsem, E. / Yoshino, T. / Bodoky, G. / Prausová, J. / Garcia-Carbonero, R. / Ciuleanu, T. / Garcia Alfonso, P. / Portnoy, D. / Cohn, A. et al. | 2016
- 2090
-
Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trialIkeda, M. / Shimizu, S. / Sato, T. / Morimoto, M. / Kojima, Y. / Inaba, Y. / Hagihara, A. / Kudo, M. / Nakamori, S. / Kaneko, S. et al. | 2016
- 2097
-
Toward the molecular dissection of peritoneal pseudomyxomaPietrantonio, F. / Perrone, F. / Mennitto, A. / Gleeson, E. M. / Milione, M. / Tamborini, E. / Busico, A. / Settanni, G. / Berenato, R. / Caporale, M. et al. | 2016
- 2103
-
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trialsYang, J. C. / Sequist, L. V. / Zhou, C. / Schuler, M. / Geater, S. L. / Mok, T. / Hu, C. P. / Yamamoto, N. / Feng, J. / O'Byrne, K. et al. | 2016
- 2111
-
Chromoplectic TPM3–ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinibMansfield, A. S. / Murphy, S. J. / Harris, F. R. / Robinson, S. I. / Marks, R. S. / Johnson, S. H. / Smadbeck, J. B. / Halling, G. C. / Yi, E. S. / Wigle, D. et al. | 2016
- 2117
-
Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancerKinoshita, T. / Muramatsu, R. / Fujita, T. / Nagumo, H. / Sakurai, T. / Noji, S. / Takahata, E. / Yaguchi, T. / Tsukamoto, N. / Kudo-Saito, C. et al. | 2016
- 2124
-
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancerLiu, J. F. / Moore, K. N. / Birrer, M. J. / Berlin, S. / Matulonis, U. A. / Infante, J. R. / Wolpin, B. / Poon, K. A. / Firestein, R. / Xu, J. et al. | 2016
- 2131
-
Is the Gleason score the driver for the treatment decision-making of patients with castration-resistant prostate cancer in the new era of the anti-androgenic therapies?Roviello, G. / Generali, D. et al. | 2016
- 2133
-
Reply to the letter to the editor ‘Epstein–Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma’ by Tan et al.Kim, S. J. / Kim, W. S. et al. | 2016
- 2134
-
Utilisation of the ESMO-MCBS in practice of HTAWild, C. / Grössmann, N. / Bonanno, P. V. / Bucsics, A. / Furst, J. / Garuoliene, K. / Godman, B. / Gulbinovič, J. / Jones, J. / Pomorski, M. K. et al. | 2016
- 2136
-
Reply to the letter to the editor ‘Utilisation of the ESMO-MCBS in practice of HTA’ by Wild et al.Cherny, N. I. / Sullivan, R. / Dafni, U. / Bogaerts, J. / Kerst, J. M. / Zielinski, C. / Piccart, M. J. / de Vries, E. G. et al. | 2016
- 2137
-
Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trialCeccarelli, G. / Schietroma, I. / Corano Scheri, G. / d'Ettorre, G. / Vullo, V. et al. | 2016
- 2138
-
Reply to the letter to the editor ‘Erroneous conclusions about the association between light alcohol drinking and the risk of cancer: comments on Bagnardi et al.'s meta-analysis, by S.-K. Myung’Bagnardi, V. / Botteri, E. / La Vecchia, C. et al. | 2016
- 2138
-
Erroneous conclusions about the association between light alcohol drinking and the risk of cancer: comments on Bagnardi et al.'s meta-analysisMyung, S. K. et al. | 2016
- 2138
-
reply to the letter to the editor ‘Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trial’ by Ceccarelli et al.Lacouture, M. E. et al. | 2016
- i1
-
Progress in the treatment of ovarian cancer—lessons from homologous recombination deficiency—the first 10 yearsKaye, S. B. et al. | 2016
- i4
-
Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancerKrzystyniak, J. / Ceppi, L. / Dizon, D. S. / Birrer, M. J. et al. | 2016
- i11
-
Opportunities in immunotherapy of ovarian cancerCoukos, G. / Tanyi, J. / Kandalaft, L. E. et al. | 2016
- i16
-
The molecular pathology of ovarian serous borderline tumors†Malpica, A. / Wong, K. K. et al. | 2016
- i20
-
Management of borderline ovarian tumorsdu Bois, A. / Trillsch, F. / Mahner, S. / Heitz, F. / Harter, P. et al. | 2016
- i23
-
Molecular imaging in ovarian cancerReyners, A. K. / Broekman, K. E. / Glaudemans, A. W. / Brouwers, A. H. / Arts, H. J. / van der Zee, A. G. / de Vries, E. G. / Jalving, M. et al. | 2016
- i30
-
Neoadjuvant chemotherapy in ovarian cancer revisitedMahner, S. / Trillsch, F. / Chi, D. / Harter, P. / Pfisterer, J. / Hilpert, F. / Burges, A. / Weissenbacher, T. / du Bois, A. et al. | 2016
- i33
-
Anti-angiogenic agents in ovarian cancer: past, present, and futureMonk, B. J. / Minion, L. E. / Coleman, R. L. et al. | 2016
- i40
-
PARP inhibitors in ovarian cancerLedermann, J. A. et al. | 2016
- i45
-
Low-grade serous carcinoma of the ovary or peritoneumGershenson, D. M. et al. | 2016
- i50
-
Clear-cell carcinoma of the ovaryFujiwara, K. / Shintani, D. / Nishikawa, T. et al. | 2016
- i53
-
Mucinous epithelial ovarian carcinomaPerren, T. J. et al. | 2016
- i58
-
Optimal primary therapy of ovarian cancerBookman, M. A. et al. | 2016
- i63
-
Recurrent ovarian cancerPujade-Lauraine, E. / Combe, P. et al. | 2016
- i66
-
Patient-reported outcomes (PRO) in ovarian cancer clinical trials—lost opportunities and lessons learnedFriedlander, M. / Mercieca-Bebber, R. L. / King, M. T. et al. | 2016
- i72
-
Advanced ovarian cancer: 20 years of ovarian cancer treatmentPoveda, A. / Romero, I. et al. | 2016
- ii1
-
P-002 Suppression of lipocalin-2 promotes the epithelial-to-mesenchymal transition in human colorectal cancer cellsKim, S. L. / Kim, S. W. / Park, Y. R. et al. | 2016
- ii1
-
P-004 Immunohistochemical Expression of LRG5 and CD44 in Colorectal Polyps and Adenocarcinomas: Implications for CarcinogenesisYildiz, D. / Balci, M. / Yildiz, S. et al. | 2016
- ii1
-
P-003 Extended Mutational Profiling for Metastatic Colorectal Cancer (CRC): beyond RAS Molecular Spectrum of KRAS-NRAS-BRAF and PI3K in Cancer ColorectalOtero, S. / Saldias, P. / Sanchez, M. / Colica, M. / Bramuglia, G. / Jankilevich, G. et al. | 2016
- ii1
-
P-001 Jointly alterations of voltage-gated Na+ channel SCN5A and E-cadherin genes may impact tumor cell proliferation in human colorectal cancerTuncel, H. / Shimamto, F. / Erdamar, S. / Korpinar, M. A. et al. | 2016
- ii2
-
P-005 Prognostic significance of the frequency of primary cilia in cells of small bowel and colorectal adenocarcinomaKupec, M. / Dvorak, J. / Hadzi Nikolov, D. / Dusek, L. / Filipova, A. / Richter, I. / Buka, D. / Ryska, A. / Mokry, J. / Filip, S. et al. | 2016
- ii2
-
P-006 Hypermethylation of APC, CDH13, MLH1, MGMT, P16 and RASSF1A promoter regions in patients with colorectal cancerKit, O. / Vodolazhsky, D. / Timoshkina, N. / Vladimirova, L. / Dvadnenko, K. / Kutilin, D. et al. | 2016
- ii2
-
P-007 Comparison of methods for measuring total cell-free DNA and KRAS mutations in plasma from metastatic colorectal cancer patientsDemuth, C. / Spindler, K. L. / Johansen, J. S. / Pallisgaard, N. / Nielsen, D. / Hoegdall, E. / Vittrup, B. / Sørensen, B. et al. | 2016
- ii3
-
P-009 Inhibition of Gastrointestinal Neuroendocrine Tumor by A New Marker of Normal Neuroendocrine CellsPan, B. / Zhang, T. / Zhao, C. / Liu, Y. / Guo, Y. et al. | 2016
- ii3
-
P-010 Next generation sequencing mutational analysis of primary and metastatic colorectal cancer samples in relationship to efficacy of cetuximab-based therapyNemecek, R. / Berkovcova, J. / Slaby, O. / Svoboda, M. et al. | 2016
- ii3
-
P-008 Plasma lipidome of patients with advanced colorectal cancerFigueiredo, A. / Serafim, P. / Azzolini, A. / lo Turco, E. / Silva, I. / Forones, N. et al. | 2016
- ii3
-
P-011 Tumor budding is associated with low expression of miRNA-148a and miRNA-625-3p in colorectal cancerBaltruskeviciene, E. / Schveigert, D. / Mickys, U. / Suziedelis, K. / Aleknavicius, E. et al. | 2016
- ii4
-
P-014 Are RHOA, CSNK1A1, DVL2, FZD8 and LRP5 Genes Novel Biomarkers in the conversion from Intestinal Metaplasia to Gastric Cancer?Demirci, U. / Örenay Boyacıoğlu, S. / Kasap, E. / Bilgiç, F. / Gerçeker, E. / Yıldırım, H. / Baykan, A. / Ellidokuz, E. / Yüceyar, M. / Korkmaz, M. et al. | 2016
- ii4
-
P-013 Prognostic significance of cyclin D1 and p21 (WAF1/CIP1) in Gastric CancerMichalaki, V. / Theodosopoulos, T. / Dafnios, N. / Vezakis, A. / Karvouni, E. / Papadimitriou, C. et al. | 2016
- ii4
-
P-012 CCL2 expression is correlated with Snail expression and affects the prognosis of patients with gastric cancerZhang, J. / Yan, Y. / Wang, J. et al. | 2016
- ii5
-
P-016 Circulating mRNA expression of CD133, SNAIL, ZEB1 and ZHX as biomarkers in gastric and esophageal cancerLongo Muñoz, F. / Earl, J. / Martinez Avila, J. / Rodriguez Garrote, M. / Guerrero, C. / Galindo, J. / Priego, P. / Rodriguez, G. / García-Moreno, F. / Lopez, F. et al. | 2016
- ii5
-
P-015 Detection of gene сopy number variation as predictive markers for metastases in patients with gastric cancerKit, O. / Kutilin, D. / Vodolazhsky, D. / Tatimov, M. / Maslov, A. / Vladimirova, L. et al. | 2016
- ii5
-
P-017 Analysis of microRNA expression in Gastroenteropancreatic Neuroendocrine TumorVega Neira, S. J. / Torres Carvajal, M. M. / Barrera Herrera, L. / Andrade Perez, R. / Lopez Panqueva, R. et al. | 2016
- ii6
-
P-020 Targeting multidrug resistance – associated protein 4 (MRP4/ABCC4) in pancreatic cancerMay, M. / Alejandro, C. / Gomez, N. / Diez, F. / Copsel, S. / Iturbe, J. / Mohr, N. / Fernandez, N. / Shayo, C. / Davio, C. et al. | 2016
- ii6
-
P-018 Assessment of therapeutic potential of arsenic trioxide in the management of human hepatocellular carcinomaDugo, E. / Yedjou, C. / Stevens, J. / Tchounwou, P. et al. | 2016
- ii6
-
P-019 Use of serum levels of cytokine TGF β1 in detection of Hepatocellular carcinoma in patients with chronic liver diseaseMehmedovic, A. / Prnjavorac, B. / Vukobrat- Bijedić, Z. et al. | 2016
- ii7
-
P-021 Tanshinone IIA can inhibit human pancreatic carcinoma BxPC3 cells through decreasing the protein expressions of IGFR, EGFR, VEGFR and blocking both Ras/Raf/MEK/ERK and Ras/PI3K/AKT/mTOR pathway in vitro and in vivoSu, C. C. et al. | 2016
- ii7
-
P-024 Carcinoembryonic antigen (CEA) and the carcinoma antigen 19-9 (CA 19-9) together in early diagnosis of Stage I-II colorectal adenocarcinoma. A case-control studyLumachi, F. / Chiara, G. / Tozzoli, R. / Lo Re, G. / Basso, S. et al. | 2016
- ii7
-
P-022 Predictive biomarkers of pathologic response to preoperative chemoradiotherapy in locally advanced rectal cancerJankovic, R. / Stojanovic-Rundic, S. / Micev, M. / Krivokapic, Z. / Nikolić, V. / Popov, I. / Gavrilovic, D. / Plesinac-Karapandzic, V. / Djuric-Stefanovic, A. / Radulovic, S. et al. | 2016
- ii8
-
P-026 Assessment of lymph nodes for micrometastasis in high risk patients with colorectal cancerBotiralieva, G. / Nishanov, D. / Navruzov, S. et al. | 2016
- ii8
-
P-027 Cancer stem cells marker CD44 and Notch activation predict unfavorable prognosis in metastatic colon cancer patients treated with anti VEGF-therapyNegri, F. V. / Bozzetti, C. / Azzoni, C. / Bottarelli, L. / Squadrilli, A. / Pedrazzi, G. / Lagrasta, C. / Tamagnini, I. / Bisagni, A. / Porzio, R. et al. | 2016
- ii8
-
P-025 Prognostic markers to predict efficacy of 5-FU rechallenge as third line chemotherapy in metastatic colorectal cancerChung, I. J. / Kim, K. / Shim, H. J. / Hwang, J. E. / Bae, W. K. / Cho, S. H. et al. | 2016
- ii9
-
P-028 Analysis of KRAS and NRAS mutations in Greek patients with metastatic Colorectal Cancer (mCRC) on the registry of the Gastro-intestinal Cancer Study Group (GIC-SG)Souglakos, J. / Saridaki, Z. / Gouges, N. / Voutsina, A. / Tzardi, M. / Kalikaki, A. / Sfakianaki, M. / Athanasiadis, A. / Xynos, E. / Boukovinas, I. et al. | 2016
- ii9
-
P-029 Prognostic analysis of colon cancer patients using elastic lamina invasion and ascitic CEALee, I. K. / Lee, Y. S. / Oh, S. T. et al. | 2016
- ii9
-
P-032 A complete blood count as a prognostic marker in patients with metastatic colorectal cancer (mCRC)Krakowska, M. / Debska-Szmich, S. / Czernek, U. / Czyzykowski, R. / Potemski, P. et al. | 2016
- ii9
-
P-030 Tumor-infiltrating lymphocytes (TILs) density as prognostic determinant in stage II colorectal cancerRicci, V. / Comino, A. / Vivenza, D. / Granetto, C. / Lo Nigro, C. / Ferrero, M. / Merlano, M. C. et al. | 2016
- ii10
-
P-033 Metabolic analysis of advanced Colorectal Cancer Tissues Using Two-Dimensional NMR SpectroscopyKim, S. / Baek, I. K. / Cho, Y. K. et al. | 2016
- ii10
-
P-034 The potential of extravasated platelet aggregation as a surrogate marker for overall survival in patients with advanced gastric cancer treated by preoperative docetaxel, cisplatin, and S-1Fushida, S. / Saito, H. / Kurata, T. / Kinoshita, J. / Oyama, K. / Miyashita, T. / Ohta, T. et al. | 2016
- ii10
-
P-035 Simultaneous carcinoembryonic antigen (CEA), carcinoma antigen 19-9 (CA 19-9) and 125 (CA-125) measurement in patients with gastric cancer (stage IA-IB): a case-control studyLumachi, F. / Chiara, G. / Tozzoli, R. / Lo Re, G. / Basso, S. et al. | 2016
- ii11
-
P-036 Long Interspersed Nuclear Element (LINE)-1 Methylation Level as a Molecular Marker of Early Gastric CancerChung, W. C. / Choi, S. A. et al. | 2016
- ii11
-
P-037 The role of carcino-embryonic antigen testing among western patients with resected gastric cancerGreenleaf, E. / Hollenbeak, C. / Wong, J. / Mirkin, K. A. et al. | 2016
- ii11
-
P-038 MET activation via exon 14 skipping mutations (METex14del): gastrointestinal prevalence and sensitivity to MET inhibitor AMG337Cecchi, F. / Rabizadeh, S. / Weingarten, P. / Tsai, C. / Zhou, L. / Hembrough, T. et al. | 2016
- ii12
-
P-039 5-Fluorouracil Degradation Rate in Patients with Recurrent Gastrointestinal Cancer Treated with Metronomic CapecitabineRoberto, M. / Romiti, A. / Lionetto, L. / D'Antonio, C. / Onesti, C. / Botticelli, A. / Milano, A. / Falcone, R. / Occhipinti, M. / Mazzuca, F. et al. | 2016
- ii12
-
P-041 IKAROS: a potential prognostic marker in pancreatic ductal adenocarcinomaCruz Ramos, M. / Rodriguez-Remirez, M. / Minguez, P. / Cebrian, A. / del Puerto-Nevado, L. / Celdran, A. / Garcia-Foncillas Lopez, J. et al. | 2016
- ii12
-
P-040 Dihydropyrimidine Dehydrogenase (DPD) and Thymidylate Synthase (TYMS) Germline Pharmacogenomics Role in Predicting Fluoropyrimidines Toxicity in Patients with Gastrointestinal (GI) MalignanciesKhushman, M. / Hosein, P. / Cameron, D. / Clarkson, D. / Butler, T. / Vu, M. / Norden, C. / Baliem, W. / Jones, V. / Bhadkamkar, S. et al. | 2016
- ii13
-
P-042 The genetic profile of pancreatic circulating tumor cellsApostolou, P. / Toloudi, M. / Papasotiriou, I. et al. | 2016
- ii13
-
P-044 Primary anorectal melanomas: rare entity, interest of targeting CKITOualla, K. / Amarti, A. / El Mesbahi, O. / Mellas, N. / Tizniti, S. et al. | 2016
- ii13
-
P-045 Resistant form of helicobacter pylori in development of stomach MALT lymphomaMallaev, M. / Yusupbekov, A. et al. | 2016
- ii13
-
P-043 Significance of bcl-2 in rectal cancer recurrencesBotiralieva, G. / Navruzov, S. / Nishanov, D. / Shomansurova, N. et al. | 2016
- ii14
-
P-046 Low-dose paclitaxel suppresses the induction of M2 macrophages in gastric cancerYamaguchi, T. / Fushida, S. / Ohta, T. et al. | 2016
- ii14
-
P-048 Prognostic Impact of CA19-9 Level at Diagnosis in Resected Stage I-III Pancreatic Adenocarcinoma: a US Population StudyMirkin, K. / Hollenbeak, C. / Wong, J. et al. | 2016
- ii14
-
P-047 Effectiveness of TACE as bridge therapy for liver transplant in hepatocellular carcinomaRibeiro, C. / Barreira, J. / Parmanande, A. / Semedo, P. / Semedo, M. / Silva, M. / Costa, N. / Ribeiro, V. / Coimbra, E. / Barroso, E. et al. | 2016
- ii15
-
P-051 Preliminary clinical and pathologic characteristics of patients treated in second-line (2L) with 25 cycles (Cy) or more of FOLFIRI + Aflibercept (FA)Pericay, C. / Martínez-Lago, N. / Corral, M. / Macías Declara, I. / Donnay, O. / Juez Martel, I. / García-Paredes, B. / Méndez Méndez, J. C. / Cacho Lanvin, D. / González-Astorga, B. et al. | 2016
- ii15
-
P-050 The pharmacological costs of first-line therapies in unselected advanced colorectal cancer patients: a review of published phase III trialsGiuliani, J. / Bonetti, A. et al. | 2016
- ii15
-
P-049 A population study of correlation between the treatment rate for monoclonal antibodies (Mabs) and mortality rate in patients with metastatic colorectal cancer (mCRC) in RussiaFedyanin, M. / Polyanskaya, E. / Sekhina, O. / Tryakin, A. / Tjulandin, S. et al. | 2016
- ii16
-
P-054 The clinical predictor of antitumor efficacy of cetuximab based regimen in first-line therapy to unresectable metastatic colorectal cancerTanioka, H. / Nagasaka, T. / Asano, M. / Ikeda, K. / Yoshida, R. / Waki, N. / Ishizaki, M. / Yamashita, K. et al. | 2016
- ii16
-
P-052 Phase II study of biweekly cetuximab and irinotecan as third-line therapy in patients with pre-treated KRAS exon2 wild-type metastatic colorectal cancerOsumi, H. / Shinozaki, E. / Suenaga, M. / Matsusaka, S. / Nakayama, I. / Wakatsuki, T. / Ogura, M. / Ozaka, M. / Takashi, I. / Takahari, D. et al. | 2016
- ii16
-
P-053 Updated analysis of induction & maintenance adjuvant chemotherapy with 3-month oxaliplatin-based regimen followed by 3 months capecitabine in patients with stage III and high-risk stage II colorectal cancer :(JSWOG C2)Tanioka, H. / Yamashita, K. / Tsuruta, A. / Tsuji, A. / Nagasaka, T. / Okumura, H. / Oka, Y. / Inukai, M. / Yamakawa, T. / Yamatsuji, T. et al. | 2016
- ii17
-
P-057 Body Composition (BC), beyond Body Mass Index (BMI) and sarcopenia, has a major prognostic impact on patients with refractory advanced Colorectal Cancer (aCRC)Van Bogaert, C. / Vandeputte, C. / Ameye, L. / Paesmans, M. / Guiot, T. / Deleporte, A. / Charette, N. / Hendlisz, A. et al. | 2016
- ii17
-
P-055 Prospective evaluation for chemotherapy-induced nausea and vomiting in colorectal cancer receiving oxaliplatin-based chemotherapy of moderate emetic riskShimokawa, M. / Hayashi, T. / Kogawa, T. / Matsui, R. / Suzuki, K. / Saeki, T. / Aiba, K. / Tamura, K. et al. | 2016
- ii17
-
P-056 Outcome of maintenance therapy in patients who achieved NED after liver resection for mCRCAl-Hajeili, M. / Serzan, M. / Prins, P. / Marshall, J. et al. | 2016
- ii18
-
P-058 Nutritional status and survival in elderly patients with colorectal cancerBarao, K. / Fucuta, P. / Vicente, M. / Forones, N. et al. | 2016
- ii18
-
P-060 Endoscopic colorectal stenting for malignant large bowel obstruction comparing to surgeryKang, D. H. / Kim, H. W. / Choi, C. W. / Park, S. B. / Kim, S. J. / Nam, H. S. / Jang, H. H. / Lee, S. B. / Lee, S. H. / Park, J. M. et al. | 2016
- ii18
-
P-059 Phase I trial of FOLFOXIRI in combination with Panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer (JACCRO CC-14)Tsuji, A. / Nakamura, M. / Ogawa, M. / Satake, H. / Kotake, T. / Hatachi, Y. / Takagane, A. / Okita, Y. / Nakamura, K. / Onikubo, T. et al. | 2016
- ii19
-
P-063 Effect of age on treatment effect and tolerability of SIRT when added to mFOLFOX chemotherapy in patients with metastatic colorectal cancer (mCRC) – results from the SIRFLOX studyvan Hazel, G. / Heinemann, V. / Sharma, N. / Findlay, M. / Ricke, J. / Peeters, M. / Gebski, V. / Van Buskirk, M. / Gibbs, P. et al. | 2016
- ii19
-
P-061 Real-world experiences of use of aflibercept in patients with stage IV colorectal cancer in the North-West of EnglandFlaum, N. / Kurup, R. / Tong, D. / Alchawaf, A. / Lau, S. / Harle, A. / Hajri, R. / Williamson, D. / Papaxoinos, G. / Mullamitha, S. et al. | 2016
- ii19
-
P-062 Correlation of histological Tumor Regression Grading (TRG) with radiological response and long-term outcome after preoperative chemotherapy for Colorectal Liver Metastases: a propensity score matching analysisInada, R. / Murotani, K. / Iwamoto, S. / Kaibori, M. / Ishizaki, M. / Iida, H. / Matsui, K. / Oishi, M. / Mastumoto, T. / Michiura, T. et al. | 2016
- ii20
-
P-066 New methods of detecting oxaliplatin-induced peripheral sensory neuropathy in patients undergoing adjuvant treatment with 5-fluorouracil and oxaliplatin for colon cancerSzpejewska, J. / Mørch, C. D. / Yilmaz, M. / Arendt-Nielsen, L. / Falkmer, U. et al. | 2016
- ii20
-
P-065 Surveillance colonoscopy after endoscopic resection of early colon cancerKim, J. O. / Jeon, S. R. / Kim, H. G. / Lee, J. S. et al. | 2016
- ii20
-
P-064 Bevacizumab with chemodoublet as conversion-to-resectability therapy for patients with liver metastases of colorectal cancerRistic, M. / Stanic, N. / Radosavljevic, D. / Ristic, D. / Spasic, J. et al. | 2016
- ii21
-
P-070 The risk of thromboembolic events in upper GI cancer patients undergoing preoperative chemotherapyMohan Annet Jesmine, M. / Papavasileiou, V. / Chatzigeorgiou, V. / Kamposioras, K. et al. | 2016
- ii21
-
P-068 Cetuximab in addition to oxaliplatin, fluorouracil and radiotherapy for patients with esophageal cancer treated without surgeryAlexandersson von Döbeln, G. / Wagenius, G. / Holtved, E. / Hjortland Geir, O. / Nilsson, M. / Baeksgaard, L. et al. | 2016
- ii21
-
P-069 Neoadjuvant chemotherapy for esophageal cancer: comparison of DCS (DTX/CDDP/S-1) chemotherapy with FAN (5-FU/ADM/Nedaplatin) chemotherapyShimoji, H. / Nishimaki, T. / Karimata, H. / Hayasaka, K. et al. | 2016